ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID NEK1_HUMAN Reviewed; 1258 AA. AC Q96PY6; G5E9Z3; Q05DG5; Q14CB7; Q5H9T1; Q6PIB8; Q96SS2; Q9H6P7; Q9Y594; DT 13-AUG-2002, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-2002, sequence version 2. DT 28-JAN-2026, entry version 212. DE RecName: Full=Serine/threonine-protein kinase Nek1; DE EC=2.7.11.1 {ECO:0000269|PubMed:20230784}; DE AltName: Full=Never in mitosis A-related kinase 1; DE Short=NimA-related protein kinase 1; DE AltName: Full=Renal carcinoma antigen NY-REN-55; GN Name=NEK1; Synonyms=KIAA1901; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11572484; DOI=10.1093/dnares/8.4.179; RA Nagase T., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XXI. The RT complete sequences of 60 new cDNA clones from brain which code for large RT proteins."; RL DNA Res. 8:179-187(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLY-724. RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Bone marrow, and Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 91-1258 (ISOFORM 5), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1258. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 444-1258 (ISOFORM 2), AND IDENTIFICATION AS A RP RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=15604234; DOI=10.1158/0008-5472.can-04-2243; RA Polci R., Peng A., Chen P.L., Riley D.J., Chen Y.; RT "NIMA-related protein kinase 1 is involved early in the ionizing radiation- RT induced DNA damage response."; RL Cancer Res. 64:8800-8803(2004). RN [9] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=18843199; DOI=10.4161/cc.7.20.6815; RA Chen Y., Chen P.L., Chen C.F., Jiang X., Riley D.J.; RT "Never-in-mitosis related kinase 1 functions in DNA damage response and RT checkpoint control."; RL Cell Cycle 7:3194-3201(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414; SER-418; SER-428; RP SER-653; SER-798; SER-834; SER-868 AND SER-881, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP FUNCTION IN PHOSPHORYLATION OF VDAC1, AND CATALYTIC ACTIVITY. RX PubMed=20230784; DOI=10.1016/j.bbrc.2010.03.077; RA Chen Y., Gaczynska M., Osmulski P., Polci R., Riley D.J.; RT "Phosphorylation by Nek1 regulates opening and closing of voltage dependent RT anion channel 1."; RL Biochem. Biophys. Res. Commun. 394:798-803(2010). RN [14] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INVOLVEMENT IN RP DIGENIC SHORT-RIB THORACIC DYSPLASIA 3/6 WITH POLYDACTYLY. RX PubMed=21211617; DOI=10.1016/j.ajhg.2010.12.004; RA Thiel C., Kessler K., Giessl A., Dimmler A., Shalev S.A., von der Haar S., RA Zenker M., Zahnleiter D., Stoess H., Beinder E., Abou Jamra R., Ekici A.B., RA Schroeder-Kress N., Aigner T., Kirchner T., Reis A., Brandstaetter J.H., RA Rauch A.; RT "NEK1 mutations cause short-rib polydactyly syndrome type majewski."; RL Am. J. Hum. Genet. 88:106-114(2011). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-156; SER-428; THR-661; RP SER-664; SER-868; SER-881 AND SER-1052, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1052, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH RP CFAP410 AND SPATA7 BY MASS SPECTROMETRY, AND INTERACTION WITH CFAP410. RX PubMed=26167768; DOI=10.1038/ncb3201; RG UK10K Consortium; RG University of Washington Center for Mendelian Genomics; RA Wheway G., Schmidts M., Mans D.A., Szymanska K., Nguyen T.M., Racher H., RA Phelps I.G., Toedt G., Kennedy J., Wunderlich K.A., Sorusch N., RA Abdelhamed Z.A., Natarajan S., Herridge W., van Reeuwijk J., Horn N., RA Boldt K., Parry D.A., Letteboer S.J., Roosing S., Adams M., Bell S.M., RA Bond J., Higgins J., Morrison E.E., Tomlinson D.C., Slaats G.G., RA van Dam T.J., Huang L., Kessler K., Giessl A., Logan C.V., Boyle E.A., RA Shendure J., Anazi S., Aldahmesh M., Al Hazzaa S., Hegele R.A., Ober C., RA Frosk P., Mhanni A.A., Chodirker B.N., Chudley A.E., Lamont R., RA Bernier F.P., Beaulieu C.L., Gordon P., Pon R.T., Donahue C., RA Barkovich A.J., Wolf L., Toomes C., Thiel C.T., Boycott K.M., McKibbin M., RA Inglehearn C.F., Stewart F., Omran H., Huynen M.A., Sergouniotis P.I., RA Alkuraya F.S., Parboosingh J.S., Innes A.M., Willoughby C.E., Giles R.H., RA Webster A.R., Ueffing M., Blacque O., Gleeson J.G., Wolfrum U., RA Beales P.L., Gibson T., Doherty D., Mitchison H.M., Roepman R., RA Johnson C.A.; RT "An siRNA-based functional genomics screen for the identification of RT regulators of ciliogenesis and ciliopathy genes."; RL Nat. Cell Biol. 17:1074-1087(2015). RN [19] RP INVOLVEMENT IN OFD2, AND VARIANTS OFD2 THR-155 AND 409-TRP--GLU-1258 DEL. RX PubMed=27530628; DOI=10.1038/ejhg.2016.103; RA Monroe G.R., Kappen I.F., Stokman M.F., Terhal P.A., van den Boogaard M.H., RA Savelberg S.M., van der Veken L.T., van Es R.J., Lens S.M., Hengeveld R.C., RA Creton M.A., Janssen N.G., Mink van der Molen A.B., Ebbeling M.B., RA Giles R.H., Knoers N.V., van Haaften G.; RT "Compound heterozygous NEK1 variants in two siblings with oral-facial- RT digital syndrome type II (Mohr syndrome)."; RL Eur. J. Hum. Genet. 24:1752-1760(2016). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-10; LYS-25; VAL-76; PRO-294; GLY-355; RP VAL-463; THR-598; GLY-724; ASN-745; GLU-883 AND ASN-1180. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANTS SRTD6 ARG-145 AND SER-253. RX PubMed=22499340; DOI=10.1136/jmedgenet-2011-100717; RA El Hokayem J., Huber C., Couve A., Aziza J., Baujat G., Bouvier R., RA Cavalcanti D.P., Collins F.A., Cordier M.P., Delezoide A.L., Gonzales M., RA Johnson D., Le Merrer M., Levy-Mozziconacci A., Loget P., RA Martin-Coignard D., Martinovic J., Mortier G.R., Perez M.J., Roume J., RA Scarano G., Munnich A., Cormier-Daire V.; RT "NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type RT but not in Beemer Langer cases."; RL J. Med. Genet. 49:227-233(2012). RN [22] RP INVOLVEMENT IN ALS24, AND VARIANTS 784-ARG--GLU-1258 DEL AND RP 1008-SER--GLU-1258 DEL. RX PubMed=26945885; DOI=10.1093/brain/aww033; RA Brenner D., Mueller K., Wieland T., Weydt P., Boehm S., Lule D., RA Huebers A., Neuwirth C., Weber M., Borck G., Wahlqvist M., Danzer K.M., RA Volk A.E., Meitinger T., Strom T.M., Otto M., Kassubek J., Ludolph A.C., RA Andersen P.M., Weishaupt J.H.; RT "NEK1 mutations in familial amyotrophic lateral sclerosis."; RL Brain 139:E28-E28(2016). RN [23] RP INVOLVEMENT IN ALS24, AND VARIANTS HIS-261 AND 550-ARG--GLU-1258 DEL. RX PubMed=27455347; DOI=10.1038/ng.3626; RA Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., RA Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., RA Shatunov A., Sproviero W., Smith B.N., van Es M.A., Topp S.D., Kenna A., RA Miller J.W., Fallini C., Tiloca C., McLaughlin R.L., Vance C., Troakes C., RA Colombrita C., Mora G., Calvo A., Verde F., Al-Sarraj S., King A., RA Calini D., de Belleroche J., Baas F., van der Kooi A.J., de Visser M., RA Ten Asbroek A.L., Sapp P.C., McKenna-Yasek D., Polak M., Asress S., RA Munoz-Blanco J.L., Strom T.M., Meitinger T., Morrison K.E., Lauria G., RA Williams K.L., Leigh P.N., Nicholson G.A., Blair I.P., Leblond C.S., RA Dion P.A., Rouleau G.A., Pall H., Shaw P.J., Turner M.R., Talbot K., RA Taroni F., Boylan K.B., Van Blitterswijk M., Rademakers R., RA Esteban-Perez J., Garcia-Redondo A., Van Damme P., Robberecht W., Chio A., RA Gellera C., Drepper C., Sendtner M., Ratti A., Glass J.D., Mora J.S., RA Basak N.A., Hardiman O., Ludolph A.C., Andersen P.M., Weishaupt J.H., RA Brown R.H. Jr., Al-Chalabi A., Silani V., Shaw C.E., van den Berg L.H., RA Veldink J.H., Landers J.E.; RT "NEK1 variants confer susceptibility to amyotrophic lateral sclerosis."; RL Nat. Genet. 48:1037-1042(2016). CC -!- FUNCTION: Phosphorylates serines and threonines, but also appears to CC possess tyrosine kinase activity (PubMed:20230784). Involved in DNA CC damage checkpoint control and for proper DNA damage repair CC (PubMed:20230784). In response to injury that includes DNA damage, NEK1 CC phosphorylates VDAC1 to limit mitochondrial cell death CC (PubMed:20230784). May be implicated in the control of meiosis (By CC similarity). Involved in cilium assembly (PubMed:21211617). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:20230784, CC ECO:0000269|PubMed:21211617}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Binds to CBY2 (By similarity). Found in a complex with CC CFAP410, NEK1 and SPATA7 (PubMed:26167768). Interacts with CFAP410 CC (PubMed:26167768). Interacts (via Ser-1052 phosphorylated form) with CC 14-3-3 proteins (By similarity). {ECO:0000250|UniProtKB:P51954, CC ECO:0000269|PubMed:26167768}. CC -!- INTERACTION: CC Q96PY6; Q96Q42: ALS2; NbExp=2; IntAct=EBI-373615, EBI-1044902; CC Q96PY6; Q99689: FEZ1; NbExp=2; IntAct=EBI-373615, EBI-396435; CC Q96PY6; Q9UHY8: FEZ2; NbExp=2; IntAct=EBI-373615, EBI-396453; CC Q96PY6; Q5S007: LRRK2; NbExp=2; IntAct=EBI-373615, EBI-5323863; CC Q96PY6; Q04917: YWHAH; NbExp=6; IntAct=EBI-373615, EBI-306940; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15604234, CC ECO:0000305|PubMed:21211617}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250|UniProtKB:P51954}. Cytoplasm CC {ECO:0000269|PubMed:18843199}. Note=Associated with the pericentriolar CC material (PubMed:21211617). Localizes to centrosome during interphase CC and mitosis (By similarity). Translocated from cytoplasm to discrete CC nuclear foci at sites of DNA damage (PubMed:15604234). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:15604234, CC ECO:0000269|PubMed:21211617}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q96PY6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96PY6-2; Sequence=VSP_004870; CC Name=3; CC IsoId=Q96PY6-3; Sequence=VSP_035439; CC Name=4; CC IsoId=Q96PY6-4; Sequence=VSP_035435, VSP_035436; CC Name=5; CC IsoId=Q96PY6-5; Sequence=VSP_035437, VSP_035438; CC Name=6; CC IsoId=Q96PY6-6; Sequence=VSP_035436, VSP_035439; CC -!- TISSUE SPECIFICITY: High fetal expression in the brain and kidney. CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Short-rib thoracic dysplasia 6 with or without polydactyly CC (SRTD6) [MIM:263520]: A form of short-rib thoracic dysplasia, a group CC of autosomal recessive ciliopathies that are characterized by a CC constricted thoracic cage, short ribs, shortened tubular bones, and a CC 'trident' appearance of the acetabular roof. Polydactyly is variably CC present. Non-skeletal involvement can include cleft lip/palate as well CC as anomalies of major organs such as the brain, eye, heart, kidneys, CC liver, pancreas, intestines, and genitalia. Some forms of the disease CC are lethal in the neonatal period due to respiratory insufficiency CC secondary to a severely restricted thoracic cage, whereas others are CC compatible with life. Disease spectrum encompasses Ellis-van Creveld CC syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer- CC Saldino syndrome, and short rib-polydactyly syndrome. CC {ECO:0000269|PubMed:22499340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. In some cases NEK1 CC mutations result in disease phenotype in the presence of mutations in CC DYNC2H1 indicating digenic inheritance (digenic short rib-polydactyly CC syndrome 3/6 with polydactyly) (PubMed:21211617). CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Amyotrophic lateral sclerosis 24 (ALS24) [MIM:617892]: A form CC of amyotrophic lateral sclerosis, a neurodegenerative disorder CC affecting upper motor neurons in the brain and lower motor neurons in CC the brain stem and spinal cord, resulting in fatal paralysis. Sensory CC abnormalities are absent. The pathologic hallmarks of the disease CC include pallor of the corticospinal tract due to loss of motor neurons, CC presence of ubiquitin-positive inclusions within surviving motor CC neurons, and deposition of pathologic aggregates. The etiology of CC amyotrophic lateral sclerosis is likely to be multifactorial, involving CC both genetic and environmental factors. The disease is inherited in 5- CC 10% of the cases. {ECO:0000269|PubMed:26945885, CC ECO:0000269|PubMed:27455347}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Orofaciodigital syndrome 2 (OFD2) [MIM:252100]: A form of CC orofaciodigital syndrome, a group of heterogeneous disorders CC characterized by malformations of the oral cavity, face and digits, and CC associated phenotypic abnormalities that lead to the delineation of CC various subtypes. OFD2 is an autosomal recessive form characterized by CC cleft lip/palate, lobulated tongue with nodules, dental anomalies, CC maxillary hypoplasia, conductive hearing loss, polydactyly, syndactyly, CC brachydactyly, and mesomelic lower limb shortening. CC {ECO:0000269|PubMed:27530628}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH15147.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAB15207.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55209.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB67794.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB067488; BAB67794.1; ALT_INIT; mRNA. DR EMBL; CR933642; CAI45943.1; -; mRNA. DR EMBL; AC116615; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC116621; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC084724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471056; EAX04791.1; -; Genomic_DNA. DR EMBL; BC015147; AAH15147.1; ALT_SEQ; mRNA. DR EMBL; BC037790; AAH37790.1; -; mRNA. DR EMBL; BC114491; AAI14492.1; -; mRNA. DR EMBL; AK025658; BAB15207.1; ALT_INIT; mRNA. DR EMBL; AK027580; BAB55209.1; ALT_INIT; mRNA. DR EMBL; AF155113; AAD42879.1; -; mRNA. DR CCDS; CCDS47162.1; -. [Q96PY6-1] DR CCDS; CCDS56348.1; -. [Q96PY6-4] DR CCDS; CCDS56349.1; -. [Q96PY6-2] DR CCDS; CCDS56350.1; -. [Q96PY6-6] DR CCDS; CCDS56351.1; -. [Q96PY6-3] DR RefSeq; NP_001186326.1; NM_001199397.3. [Q96PY6-3] DR RefSeq; NP_001186327.1; NM_001199398.3. [Q96PY6-6] DR RefSeq; NP_001186328.1; NM_001199399.3. [Q96PY6-4] DR RefSeq; NP_001186329.1; NM_001199400.3. [Q96PY6-2] DR RefSeq; NP_001361347.1; NM_001374418.1. [Q96PY6-3] DR RefSeq; NP_001361348.1; NM_001374419.1. [Q96PY6-1] DR RefSeq; NP_036356.1; NM_012224.4. [Q96PY6-1] DR RefSeq; XP_011530306.1; XM_011532004.2. [Q96PY6-2] DR RefSeq; XP_047271687.1; XM_047415731.1. [Q96PY6-6] DR PDB; 4APC; X-ray; 2.10 A; A/B=1-328. DR PDB; 4B9D; X-ray; 1.90 A; A/B=1-328. DR PDBsum; 4APC; -. DR PDBsum; 4B9D; -. DR AlphaFoldDB; Q96PY6; -. DR SMR; Q96PY6; -. DR BioGRID; 110825; 92. DR CORUM; Q96PY6; -. DR FunCoup; Q96PY6; 4026. DR IntAct; Q96PY6; 63. DR MINT; Q96PY6; -. DR STRING; 9606.ENSP00000424757; -. DR BindingDB; Q96PY6; -. DR ChEMBL; CHEMBL5855; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96PY6; -. DR GuidetoPHARMACOLOGY; 2114; -. DR GlyGen; Q96PY6; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q96PY6; -. DR PhosphoSitePlus; Q96PY6; -. DR BioMuta; NEK1; -. DR DMDM; 22256934; -. DR jPOST; Q96PY6; -. DR MassIVE; Q96PY6; -. DR PaxDb; 9606-ENSP00000424757; -. DR PeptideAtlas; Q96PY6; -. DR ProteomicsDB; 34091; -. DR ProteomicsDB; 77788; -. [Q96PY6-1] DR ProteomicsDB; 77789; -. [Q96PY6-2] DR ProteomicsDB; 77790; -. [Q96PY6-3] DR ProteomicsDB; 77791; -. [Q96PY6-4] DR ProteomicsDB; 77792; -. [Q96PY6-5] DR Pumba; Q96PY6; -. DR TopDownProteomics; Q96PY6-3; -. [Q96PY6-3] DR Antibodypedia; 28454; 148 antibodies from 27 providers. DR DNASU; 4750; -. DR Ensembl; ENST00000439128.6; ENSP00000408020.2; ENSG00000137601.19. [Q96PY6-1] DR Ensembl; ENST00000507142.6; ENSP00000424757.2; ENSG00000137601.19. [Q96PY6-3] DR Ensembl; ENST00000510533.5; ENSP00000427653.1; ENSG00000137601.19. [Q96PY6-2] DR Ensembl; ENST00000511633.5; ENSP00000423332.1; ENSG00000137601.19. [Q96PY6-6] DR Ensembl; ENST00000512193.5; ENSP00000424938.1; ENSG00000137601.19. [Q96PY6-4] DR GeneID; 4750; -. DR KEGG; hsa:4750; -. DR MANE-Select; ENST00000507142.6; ENSP00000424757.2; NM_001199397.3; NP_001186326.1. [Q96PY6-3] DR UCSC; uc003isb.3; human. [Q96PY6-1] DR AGR; HGNC:7744; -. DR ClinPGx; PA31545; -. DR CTD; 4750; -. DR DisGeNET; 4750; -. DR GeneCards; NEK1; -. DR HGNC; HGNC:7744; NEK1. DR HPA; ENSG00000137601; Low tissue specificity. DR MalaCards; NEK1; -. DR MIM; 252100; phenotype. DR MIM; 263520; phenotype. DR MIM; 604588; gene. DR MIM; 617892; phenotype. DR OpenTargets; ENSG00000137601; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 2751; Orofaciodigital syndrome type 2. DR Orphanet; 93269; Short rib-polydactyly syndrome, Majewski type. DR VEuPathDB; HostDB:ENSG00000137601; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000158460; -. DR HOGENOM; CLU_000288_60_1_1; -. DR InParanoid; Q96PY6; -. DR OMA; ELNEEWH; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q96PY6; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PY6; -. DR PathwayCommons; Q96PY6; -. DR Reactome; R-HSA-9861718; Regulation of pyruvate metabolism. DR SignaLink; Q96PY6; -. DR SIGNOR; Q96PY6; -. DR Agora; ENSG00000137601; -. DR BioGRID-ORCS; 4750; 51 hits in 1199 CRISPR screens. DR ChiTaRS; NEK1; human. DR EvolutionaryTrace; Q96PY6; -. DR GeneWiki; NEK1; -. DR GenomeRNAi; 4750; -. DR Pharos; Q96PY6; Tchem. DR PRO; PR:Q96PY6; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q96PY6; protein. DR Bgee; ENSG00000137601; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q96PY6; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016301; F:kinase activity; IMP:CACAO. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR CDD; cd08218; STKc_Nek1; 1. DR FunFam; 3.30.200.20:FF:000097; Probable serine/threonine-protein kinase nek1; 1. DR FunFam; 1.10.510.10:FF:000172; serine/threonine-protein kinase Nek1 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF4; SERINE_THREONINE-PROTEIN KINASE NEK1; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Amyotrophic lateral sclerosis; KW ATP-binding; Cell cycle; Cell division; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Kinase; Magnesium; KW Metal-binding; Mitosis; Neurodegeneration; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase. FT CHAIN 1..1258 FT /note="Serine/threonine-protein kinase Nek1" FT /id="PRO_0000086418" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 330..360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 578..600 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 648..669 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 685..704 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1118..1171 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 344..360 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..591 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 691..700 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 156 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 414 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 418 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT MOD_RES 653 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 661 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 798 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 834 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 868 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1052 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1126 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT VAR_SEQ 398..422 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035435" FT VAR_SEQ 477..520 FT /note="Missing (in isoform 4 and isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035436" FT VAR_SEQ 478..521 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10508479" FT /id="VSP_004870" FT VAR_SEQ 522..527 FT /note="QKGQLA -> LDCDDP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035437" FT VAR_SEQ 528..1258 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035438" FT VAR_SEQ 555 FT /note="M -> MGILQNLAAMYGGRPSSSRGGKPRNKEEE (in isoform 3 and FT isoform 6)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_035439" FT VARIANT 10 FT /note="I -> F (in dbSNP:rs34214559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040900" FT VARIANT 25 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040901" FT VARIANT 76 FT /note="L -> V (in dbSNP:rs35093214)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040902" FT VARIANT 145 FT /note="G -> R (in SRTD6; dbSNP:rs431905508)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069617" FT VARIANT 155 FT /note="S -> T (in OFD2; uncertain significance; the FT nucleotide substitution creating this missense variant may FT predominantly result in aberrant splicing, with skipping of FT exon 6 and creation of a premature stop codon, possibly FT leading to nonsense-mediated mRNA decay)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089300" FT VARIANT 253 FT /note="L -> S (in SRTD6)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069618" FT VARIANT 261 FT /note="R -> H (risk factor for ALS24; dbSNP:rs200161705)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080694" FT VARIANT 294 FT /note="A -> P (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040903" FT VARIANT 355 FT /note="R -> G (in dbSNP:rs35763578)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040904" FT VARIANT 409..1258 FT /note="Missing (in OFD2; uncertain significance; the FT nucleotide substitution creating this nonsense variant may FT predominantly result in aberrant splicing)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089301" FT VARIANT 463 FT /note="A -> V (in dbSNP:rs34540355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040905" FT VARIANT 550..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080695" FT VARIANT 598 FT /note="A -> T (in dbSNP:rs33933790)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046486" FT VARIANT 717 FT /note="N -> K (in dbSNP:rs34324114)" FT /id="VAR_061743" FT VARIANT 724 FT /note="E -> G (in dbSNP:rs34099167)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_051651" FT VARIANT 745 FT /note="K -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040906" FT VARIANT 784..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080696" FT VARIANT 883 FT /note="Q -> E (in dbSNP:rs6828134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046488" FT VARIANT 1008..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080697" FT VARIANT 1180 FT /note="D -> N (in dbSNP:rs35503975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046489" FT CONFLICT 250 FT /note="N -> D (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 602 FT /note="R -> RK (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 1232 FT /note="G -> E (in Ref. 7; AAD42879)" FT /evidence="ECO:0000305" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 29..36 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 88..94 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 102..121 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 149..151 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 155..164 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 172..175 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 182..198 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 208..217 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 229..238 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 243..245 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 249..253 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 256..259 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 260..264 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 268..275 FT /evidence="ECO:0007829|PDB:4B9D" SQ SEQUENCE 1258 AA; 142828 MW; 339C4BFA56612530 CRC64; MEKYVRLQKI GEGSFGKAIL VKSTEDGRQY VIKEINISRM SSKEREESRR EVAVLANMKH PNIVQYRESF EENGSLYIVM DYCEGGDLFK RINAQKGVLF QEDQILDWFV QICLALKHVH DRKILHRDIK SQNIFLTKDG TVQLGDFGIA RVLNSTVELA RTCIGTPYYL SPEICENKPY NNKSDIWALG CVLYELCTLK HAFEAGSMKN LVLKIISGSF PPVSLHYSYD LRSLVSQLFK RNPRDRPSVN SILEKGFIAK RIEKFLSPQL IAEEFCLKTF SKFGSQPIPA KRPASGQNSI SVMPAQKITK PAAKYGIPLA YKKYGDKKLH EKKPLQKHKQ AHQTPEKRVN TGEERRKISE EAARKRRLEF IEKEKKQKDQ IISLMKAEQM KRQEKERLER INRAREQGWR NVLSAGGSGE VKAPFLGSGG TIAPSSFSSR GQYEHYHAIF DQMQQQRAED NEAKWKREIY GRGLPERGIL PGVRPGFPYG AAGHHHFPDA DDIRKTLKRL KAVSKQANAN RQKGQLAVER AKQVEEFLQR KREAMQNKAR AEGHMVYLAR LRQIRLQNFN ERQQIKAKLR GEKKEANHSE GQEGSEEADM RRKKIESLKA HANARAAVLK EQLERKRKEA YEREKKVWEE HLVAKGVKSS DVSPPLGQHE TGGSPSKQQM RSVISVTSAL KEVGVDSSLT DTRETSEEMQ KTNNAISSKR EILRRLNENL KAQEDEKGKQ NLSDTFEINV HEDAKEHEKE KSVSSDRKKW EAGGQLVIPL DELTLDTSFS TTERHTVGEV IKLGPNGSPR RAWGKSPTDS VLKILGEAEL QLQTELLENT TIRSEISPEG EKYKPLITGE KKVQCISHEI NPSAIVDSPV ETKSPEFSEA SPQMSLKLEG NLEEPDDLET EILQEPSGTN KDESLPCTIT DVWISEEKET KETQSADRIT IQENEVSEDG VSSTVDQLSD IHIEPGTNDS QHSKCDVDKS VQPEPFFHKV VHSEHLNLVP QVQSVQCSPE ESFAFRSHSH LPPKNKNKNS LLIGLSTGLF DANNPKMLRT CSLPDLSKLF RTLMDVPTVG DVRQDNLEID EIEDENIKEG PSDSEDIVFE ETDTDLQELQ ASMEQLLREQ PGEEYSEEEE SVLKNSDVEP TANGTDVADE DDNPSSESAL NEEWHSDNSD GEIASECECD SVFNHLEELR LHLEQEMGFE KFFEVYEKIK AIHEDEDENI EICSKIVQNI LGNEHQHLYA KILHLVMADG AYQEDNDE // ID TBK1_HUMAN Reviewed; 729 AA. AC Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5; DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Serine/threonine-protein kinase TBK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:25636800}; DE AltName: Full=NF-kappa-B-activating kinase {ECO:0000303|PubMed:10783893}; DE AltName: Full=T2K; DE AltName: Full=TANK-binding kinase 1 {ECO:0000303|PubMed:10581243}; GN Name=TBK1 {ECO:0000303|PubMed:10581243, ECO:0000312|HGNC:HGNC:11584}; GN Synonyms=NAK {ECO:0000303|PubMed:10783893}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TANK AND TRAF2, AND RP MUTAGENESIS OF LYS-38. RC TISSUE=Spleen; RX PubMed=10581243; DOI=10.1093/emboj/18.23.6694; RA Pomerantz J.L., Baltimore D.; RT "NF-kB activation by a signaling complex containing TRAF2, TANK, and TBK1, RT a novel IKK-related kinase."; RL EMBO J. 18:6694-6704(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN PHOSPHORYLATION OF NFKBIA AND RP IKBKB, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY. RX PubMed=10783893; DOI=10.1038/35008109; RA Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K., RA Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M., Nakanishi M.; RT "NAK is an IkappaB kinase-activating kinase."; RL Nature 404:778-782(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-388 AND GLN-570. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, MUTAGENESIS OF SER-172, AND PHOSPHORYLATION AT SER-172. RX PubMed=11839743; DOI=10.1074/jbc.m110474200; RA Kishore N., Huynh Q.K., Mathialagan S., Hall T., Rouw S., Creely D., RA Lange G., Caroll J., Reitz B., Donnelly A., Boddupalli H., Combs R.G., RA Kretzmer K., Tripp C.S.; RT "IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK- RT 2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2."; RL J. Biol. Chem. 277:13840-13847(2002). RN [7] RP INTERACTION WITH TIRAP AND TICAM1. RX PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304; RA Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., RA Akira S.; RT "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF) RT associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, RT and activates two distinct transcription factors, NF-kappa B and IFN- RT regulatory factor-3, in the Toll-like receptor signaling."; RL J. Immunol. 171:4304-4310(2003). RN [8] RP FUNCTION. RX PubMed=12692549; DOI=10.1038/ni921; RA Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., RA Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T.; RT "IKKepsilon and TBK1 are essential components of the IRF3 signaling RT pathway."; RL Nat. Immunol. 4:491-496(2003). RN [9] RP FUNCTION. RX PubMed=12702806; DOI=10.1126/science.1081315; RA Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R., Hiscott J.; RT "Triggering the interferon antiviral response through an IKK-related RT pathway."; RL Science 300:1148-1151(2003). RN [10] RP INTERACTION WITH AZI2. RX PubMed=14560022; DOI=10.1128/mcb.23.21.7780-7793.2003; RA Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T., RA Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.; RT "Identification of NAP1, a regulatory subunit of IkappaB kinase-related RT kinases that potentiates NF-kappaB signaling."; RL Mol. Cell. Biol. 23:7780-7793(2003). RN [11] RP FUNCTION IN PHOSPHORYLATION OF IRF3, AND CATALYTIC ACTIVITY. RX PubMed=14703513; DOI=10.1074/jbc.m310616200; RA Mori M., Yoneyama M., Ito T., Takahashi K., Inagaki F., Fujita T.; RT "Identification of Ser-386 of interferon regulatory factor 3 as critical RT target for inducible phosphorylation that determines activation."; RL J. Biol. Chem. 279:9698-9702(2004). RN [12] RP INTERACTION WITH TICAM1. RX PubMed=14739303; DOI=10.1074/jbc.m311629200; RA Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.; RT "Mechanisms of the TRIF-induced interferon-stimulated response element and RT NF-kappaB activation and apoptosis pathways."; RL J. Biol. Chem. 279:15652-15661(2004). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15485837; DOI=10.1074/jbc.m411037200; RA Kuai J., Wooters J., Hall J.P., Rao V.R., Nickbarg E., Li B., RA Chatterjee-Kishore M., Qiu Y., Lin L.-L.; RT "NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner and RT mediates the production of RANTES: identification of endogenous TNFR- RT interacting proteins by a proteomic approach."; RL J. Biol. Chem. 279:53266-53271(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RELA, AND CATALYTIC ACTIVITY. RX PubMed=15489227; DOI=10.1074/jbc.m409825200; RA Buss H., Dorrie A., Schmitz M.L., Hoffmann E., Resch K., Kracht M.; RT "Constitutive and interleukin-1-inducible phosphorylation of p65 RT NF-{kappa}B at serine 536 is mediated by multiple protein kinases including RT I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family RT member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and RT couples p65 to TATA-binding protein-associated factor II31-mediated RT interleukin-8 transcription."; RL J. Biol. Chem. 279:55633-55643(2004). RN [15] RP FUNCTION IN PHOSPHORYLATION OF IRF7, AND CATALYTIC ACTIVITY. RX PubMed=15367631; DOI=10.1128/jvi.78.19.10636-10649.2004; RA tenOever B.R., Sharma S., Zou W., Sun Q., Grandvaux N., Julkunen I., RA Hemmi H., Yamamoto M., Akira S., Yeh W.C., Lin R., Hiscott J.; RT "Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus RT infection and the role of viral ribonucleoprotein in the development of RT interferon antiviral immunity."; RL J. Virol. 78:10636-10649(2004). RN [16] RP INTERACTION WITH SIKE1; IRF3; TICAM1 AND RIGI. RX PubMed=16281057; DOI=10.1038/sj.emboj.7600863; RA Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.; RT "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus- RT triggered IRF-3 activation pathways."; RL EMBO J. 24:4018-4028(2005). RN [17] RP INTERACTION WITH HCV NS3 (MICROBIAL INFECTION). RX PubMed=15841462; DOI=10.1002/hep.20666; RA Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., RA Kawabe T., Omata M.; RT "Interaction between the HCV NS3 protein and the host TBK1 protein leads to RT inhibition of cellular antiviral responses."; RL Hepatology 41:1004-1012(2005). RN [18] RP FUNCTION, AND INTERACTION WITH BORNA DISEASE VIRUS P PROTEIN. RX PubMed=16155125; DOI=10.1073/pnas.0502883102; RA Unterstab G., Ludwig S., Anton A., Planz O., Dauber B., Krappmann D., RA Heins G., Ehrhardt C., Wolff T.; RT "Viral targeting of the interferon-beta-inducing Traf family member- RT associated NF-kappa-B activator (TANK)-binding kinase-1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13640-13645(2005). RN [19] RP INTERACTION WITH EXOC2, AND SUBCELLULAR LOCATION. RX PubMed=17018283; DOI=10.1016/j.cell.2006.08.034; RA Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L., RA Balakireva M.G., Romeo Y., Kopelovich L., Gale M. Jr., Yeaman C., RA Camonis J.H., Zhao Y., White M.A.; RT "RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples RT innate immune signaling to tumor cell survival."; RL Cell 127:157-170(2006). RN [20] RP DOMAIN. RX PubMed=17599067; DOI=10.1038/sj.emboj.7601773; RA Ikeda F., Hecker C.M., Rozenknop A., Nordmeier R.D., Rogov V., Hofmann K., RA Akira S., Dotsch V., Dikic I.; RT "Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in RT regulation of IFN-inducible genes."; RL EMBO J. 26:3451-3462(2007). RN [21] RP FUNCTION IN PHOSPHORYLATION OF DDX3X, AND CATALYTIC ACTIVITY. RX PubMed=18583960; DOI=10.1038/emboj.2008.126; RA Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A., RA Stefanovic A., Hantschel O., Bennett K.L., Decker T., Superti-Furga G.; RT "The DEAD-box helicase DDX3X is a critical component of the TANK-binding RT kinase 1-dependent innate immune response."; RL EMBO J. 27:2135-2146(2008). RN [22] RP INTERACTION WITH CYLD. RX PubMed=18636086; DOI=10.1038/embor.2008.136; RA Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A., Cardenas W.B., RA Yount J.S., Moran T.M., Basler C.F., Komuro A., Horvath C.M., Xavier R., RA Ting A.T.; RT "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated RT antiviral response."; RL EMBO Rep. 9:930-936(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP INTERACTION WITH SRC. RX PubMed=19419966; DOI=10.1074/jbc.m808233200; RA Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A., Anthonsen M.W.; RT "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)- RT elicited antiviral signaling."; RL J. Biol. Chem. 284:19122-19131(2009). RN [25] RP INTERACTION WITH EBOLAVIRUS PROTEIN VP35, AND AUTOPHOSPHORYLATION. RX PubMed=19153231; DOI=10.1128/jvi.01875-08; RA Prins K.C., Cardenas W.B., Basler C.F.; RT "Ebola virus protein VP35 impairs the function of interferon regulatory RT factor-activating kinases IKKepsilon and TBK-1."; RL J. Virol. 83:3069-3077(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [27] RP UBIQUITINATION BY NRDP1. RX PubMed=19483718; DOI=10.1038/ni.1742; RA Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X.; RT "The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated RT production of type I interferon."; RL Nat. Immunol. 10:744-752(2009). RN [28] RP INTERACTION WITH STING1. RX PubMed=19416887; DOI=10.1073/pnas.0900818106; RA Li Y., Li C., Xue P., Zhong B., Mao A.P., Ran Y., Chen H., Wang Y.Y., RA Yang F., Shu H.B.; RT "ISG56 is a negative-feedback regulator of virus-triggered signaling and RT cellular antiviral response."; RL Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950(2009). RN [29] RP INTERACTION WITH HSP90AA1. RX PubMed=20628368; DOI=10.1038/cr.2010.103; RA Liu X.Y., Wei B., Shi H.X., Shan Y.F., Wang C.; RT "Tom70 mediates activation of interferon regulatory factor 3 on RT mitochondria."; RL Cell Res. 20:994-1011(2010). RN [30] RP AUTOPHOSPHORYLATION, SUBUNIT, AND INTERACTION WITH GSK3B. RX PubMed=21145761; DOI=10.1016/j.immuni.2010.11.021; RA Lei C.Q., Zhong B., Zhang Y., Zhang J., Wang S., Shu H.B.; RT "Glycogen synthase kinase 3beta regulates IRF3 transcription factor- RT mediated antiviral response via activation of the kinase TBK1."; RL Immunity 33:878-889(2010). RN [31] RP INTERACTION WITH DDX3X. RX PubMed=20375222; DOI=10.1099/vir.0.020552-0; RA Yu S., Chen J., Wu M., Chen H., Kato N., Yuan Z.; RT "Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3- RT mediated beta interferon induction in human hepatocytes through RT interference with interferon regulatory factor 3 activation and dampening RT of the interaction between TBK1/IKKepsilon and DDX3."; RL J. Gen. Virol. 91:2080-2090(2010). RN [32] RP INTERACTION WITH OPTN AND TRAF3. RX PubMed=20174559; DOI=10.1371/journal.ppat.1000778; RA Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M., RA Kohl A., Elliott R.M., Macdonald A.; RT "Optineurin negatively regulates the induction of IFNbeta in response to RT RNA virus infection."; RL PLoS Pathog. 6:E1000778-E1000778(2010). RN [33] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [34] RP INVOLVEMENT IN GLC1P, TISSUE SPECIFICITY, AND VARIANTS PHE-151; ILE-306 AND RP ALA-464. RX PubMed=21447600; DOI=10.1093/hmg/ddr123; RA Fingert J.H., Robin A.L., Stone J.L., Roos B.R., Davis L.K., Scheetz T.E., RA Bennett S.R., Wassink T.H., Kwon Y.H., Alward W.L., Mullins R.F., RA Sheffield V.C., Stone E.M.; RT "Copy number variations on chromosome 12q14 in patients with normal tension RT glaucoma."; RL Hum. Mol. Genet. 20:2482-2494(2011). RN [35] RP UBIQUITINATION BY MIB1. RX PubMed=21903422; DOI=10.1016/j.immuni.2011.06.014; RA Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E.; RT "Mapping a dynamic innate immunity protein interaction network regulating RT type I interferon production."; RL Immunity 35:426-440(2011). RN [36] RP SUBCELLULAR LOCATION, AND INTERACTION WITH IFIT3 AND MAVS. RX PubMed=21813773; DOI=10.4049/jimmunol.1100963; RA Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.; RT "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging RT MAVS and TBK1."; RL J. Immunol. 187:2559-2568(2011). RN [37] RP FUNCTION IN PHOSPHORYLATION OF VPS37C, AND CATALYTIC ACTIVITY. RX PubMed=21270402; DOI=10.4049/jimmunol.1000262; RA Da Q., Yang X., Xu Y., Gao G., Cheng G., Tang H.; RT "TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through RT targeting endosomal sorting complex required for transport-I."; RL J. Immunol. 186:3023-3030(2011). RN [38] RP FUNCTION, INTERACTION WITH AZI2; TANK AND TBKBP1, AND MUTAGENESIS OF RP ASP-135; MET-690; LEU-693; LYS-694; LEU-704; ASN-708 AND LEU-711. RX PubMed=21931631; DOI=10.1371/journal.pone.0023971; RA Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W., RA Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R., Planyavsky M., RA Bennett K.L., Colinge J., Superti-Furga G.; RT "Functional dissection of the TBK1 molecular network."; RL PLoS ONE 6:E23971-E23971(2011). RN [39] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [40] RP FUNCTION IN PHOSPHORYLATION OF OPTN, AND CATALYTIC ACTIVITY. RX PubMed=21617041; DOI=10.1126/science.1205405; RA Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., RA Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D., RA Dikic I.; RT "Phosphorylation of the autophagy receptor optineurin restricts Salmonella RT growth."; RL Science 333:228-233(2011). RN [41] RP REVIEW ON FUNCTION, AND DOMAIN. RX PubMed=21042276; DOI=10.1038/onc.2010.493; RA Shen R.R., Hahn W.C.; RT "Emerging roles for the non-canonical IKKs in cancer."; RL Oncogene 30:631-641(2011). RN [42] RP FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB. RX PubMed=21138416; DOI=10.1042/bj20101701; RA Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B., RA Hough J., McIver E.G., Cohen P.; RT "Novel cross-talk within the IKK family controls innate immunity."; RL Biochem. J. 434:93-104(2011). RN [43] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=19010780; DOI=10.1074/jbc.m805905200; RA Verpooten D., Ma Y., Hou S., Yan Z., He B.; RT "Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 RT protein of herpes simplex virus 1."; RL J. Biol. Chem. 284:1097-1105(2009). RN [44] RP DEPHOSPHORYLATION AT SER-172. RX PubMed=22750291; DOI=10.1016/j.cellsig.2012.06.017; RA Zhao Y., Liang L., Fan Y., Sun S., An L., Shi Z., Cheng J., Jia W., Sun W., RA Mori-Akiyama Y., Zhang H., Fu S., Yang J.; RT "PPM1B negatively regulates antiviral response via dephosphorylating RT TBK1."; RL Cell. Signal. 24:2197-2204(2012). RN [45] RP INVOLVEMENT IN GLC1P. RX PubMed=22306015; DOI=10.1016/j.exer.2011.12.021; RA Kawase K., Allingham R.R., Meguro A., Mizuki N., Roos B., RA Solivan-Timpe F.M., Robin A.L., Ritch R., Fingert J.H.; RT "Confirmation of TBK1 duplication in normal tension glaucoma."; RL Exp. Eye Res. 96:178-180(2012). RN [46] RP INVOLVEMENT IN IIAE8, VARIANTS IIAE8 ALA-50 AND ALA-159, CHARACTERIZATION RP OF VARIANTS IIAE8 ALA-50 AND ALA-159, MUTAGENESIS OF LYS-38, RP PHOSPHORYLATION AT SER-172, AND FUNCTION. RX PubMed=22851595; DOI=10.1084/jem.20111316; RA Herman M., Ciancanelli M., Ou Y.H., Lorenzo L., Klaudel-Dreszler M., RA Pauwels E., Sancho-Shimizu V., Perez de Diego R., Abhyankar A., RA Israelsson E., Guo Y., Cardon A., Rozenberg F., Lebon P., Tardieu M., RA Heropolitanska-Pliszka E., Chaussabel D., White M.A., Abel L., Zhang S.Y., RA Casanova J.L.; RT "Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes RT simplex encephalitis of childhood."; RL J. Exp. Med. 209:1567-1582(2012). RN [47] RP UBIQUITINATION BY TRAIP. RX PubMed=22945920; DOI=10.1084/jem.20120024; RA Zhang M., Wang L., Zhao X., Zhao K., Meng H., Zhao W., Gao C.; RT "TRAF-interacting protein (TRIP) negatively regulates IFN-beta production RT and antiviral response by promoting proteasomal degradation of TANK-binding RT kinase 1."; RL J. Exp. Med. 209:1703-1711(2012). RN [48] RP UBIQUITINATION AT LYS-670 BY DTX4. RX PubMed=22388039; DOI=10.1038/ni.2239; RA Cui J., Li Y., Zhu L., Liu D., Songyang Z., Wang H.Y., Wang R.F.; RT "NLRP4 negatively regulates type I interferon signaling by targeting the RT kinase TBK1 for degradation via the ubiquitin ligase DTX4."; RL Nat. Immunol. 13:387-395(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24478431; DOI=10.1128/jvi.03021-13; RA Santiago F.W., Covaleda L.M., Sanchez-Aparicio M.T., Silvas J.A., RA Diaz-Vizarreta A.C., Patel J.R., Popov V., Yu X.J., Garcia-Sastre A., RA Aguilar P.V.; RT "Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic RT structures correlates with the inhibition of type I interferon responses."; RL J. Virol. 88:4572-4585(2014). RN [51] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24706939; DOI=10.1093/jmcb/mju015; RA Ning Y.J., Wang M., Deng M., Shen S., Liu W., Cao W.C., Deng F., Wang Y.Y., RA Hu Z., Wang H.; RT "Viral suppression of innate immunity via spatial isolation of RT TBK1/IKKepsilon from mitochondrial antiviral platform."; RL J. Mol. Cell Biol. 6:324-337(2014). RN [52] RP INVOLVEMENT IN FTDALS4, AND VARIANTS FTDALS4 ILE-306; GLU-401 AND LYS-696. RX PubMed=25943890; DOI=10.1007/s00401-015-1436-x; RA Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M., RA Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., RA Nicholson A.M., DeTure M., Knopman D.S., Josephs K.A., Parisi J.E., RA Petersen R.C., Boylan K.B., Boeve B.F., Graff-Radford N.R., Veltman J.A., RA Gilissen C., Murray M.E., Dickson D.W., Rademakers R.; RT "Whole-genome sequencing reveals important role for TBK1 and OPTN mutations RT in frontotemporal lobar degeneration without motor neuron disease."; RL Acta Neuropathol. 130:77-92(2015). RN [53] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [54] RP INVOLVEMENT IN IIAE8, AND VARIANT IIAE8 VAL-207. RX PubMed=26513235; DOI=10.1038/gene.2015.46; RA Moerk N., Kofod-Olsen E., Soerensen K.B., Bach E., Oerntoft T.F., RA Oestergaard L., Paludan S.R., Christiansen M., Mogensen T.H.; RT "Mutations in the TLR3 signaling pathway and beyond in adult patients with RT herpes simplex encephalitis."; RL Genes Immun. 16:552-566(2015). RN [55] RP INVOLVEMENT IN FTDALS4, VARIANTS FTDALS4 HIS-47; CYS-105; THR-305; GLN-308; RP GLN-357; ARG-559; VAL-571; VAL-598; GLU-643 DEL AND LYS-696, AND RP CHARACTERIZATION OF VARIANTS FTDALS4 HIS-47; GLN-308; GLN-357; ARG-559 AND RP LYS-696. RX PubMed=25803835; DOI=10.1038/nn.4000; RA Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Mueller K., RA Marroquin N., Nordin F., Huebers A., Weydt P., Pinto S., Press R., RA Millecamps S., Molko N., Bernard E., Desnuelle C., Soriani M.H., Dorst J., RA Graf E., Nordstroem U., Feiler M.S., Putz S., Boeckers T.M., Meyer T., RA Winkler A.S., Winkelman J., de Carvalho M., Thal D.R., Otto M., RA Braennstroem T., Volk A.E., Kursula P., Danzer K.M., Lichtner P., Dikic I., RA Meitinger T., Ludolph A.C., Strom T.M., Andersen P.M., Weishaupt J.H.; RT "Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal RT dementia."; RL Nat. Neurosci. 18:631-636(2015). RN [56] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25636800; DOI=10.1126/science.aaa2630; RA Liu S., Cai X., Wu J., Cong Q., Chen X., Li T., Du F., Ren J., Wu Y.T., RA Grishin N.V., Chen Z.J.; RT "Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF RT induces IRF3 activation."; RL Science 347:AAA2630-AAA2630(2015). RN [57] RP FUNCTION, AND INTERACTION WITH ICOS. RX PubMed=27135603; DOI=10.1038/ni.3463; RA Pedros C., Zhang Y., Hu J.K., Choi Y.S., Canonigo-Balancio A.J., RA Yates J.R. III, Altman A., Crotty S., Kong K.F.; RT "A TRAF-like motif of the inducible costimulator ICOS controls development RT of germinal center TFH cells via the kinase TBK1."; RL Nat. Immunol. 17:825-833(2016). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-670, AND MUTAGENESIS RP OF SER-172 AND LYS-670. RX PubMed=27692986; DOI=10.1016/j.molcel.2016.08.029; RA Lin M., Zhao Z., Yang Z., Meng Q., Tan P., Xie W., Qin Y., Wang R.F., RA Cui J.; RT "USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination RT through NLRP4 Signalosome."; RL Mol. Cell 64:267-281(2016). RN [59] RP FUNCTION. RX PubMed=27103069; DOI=10.15252/embj.201593350; RA Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A., RA Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S., RA Kabashi E., Charlet-Berguerand N.; RT "Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to RT induce motor neuron dysfunction and cell death."; RL EMBO J. 35:1276-1297(2016). RN [60] RP INTERACTION WITH TRIM26, AND FUNCTION. RX PubMed=26611359; DOI=10.1093/jmcb/mjv068; RA Ran Y., Zhang J., Liu L.L., Pan Z.Y., Nie Y., Zhang H.Y., Wang Y.Y.; RT "Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate RT antiviral immune response."; RL J. Mol. Cell Biol. 8:31-43(2016). RN [61] RP UBIQUITINATION BY RNF128. RX PubMed=27776110; DOI=10.1038/ni.3588; RA Song G., Liu B., Li Z., Wu H., Wang P., Zhao K., Jiang G., Zhang L., RA Gao C.; RT "E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63- RT linked ubiquitination of TBK1."; RL Nat. Immunol. 17:1342-1351(2016). RN [62] RP INTERACTION WITH TTLL12 AND MAVS. RX PubMed=28011935; DOI=10.4049/jimmunol.1601194; RA Ju L.G., Zhu Y., Lei P.J., Yan D., Zhu K., Wang X., Li Q.L., Li X.J., RA Chen J.W., Li L.Y., Wu M.; RT "TTLL12 Inhibits the Activation of Cellular Antiviral Signaling through RT Interaction with VISA/MAVS."; RL J. Immunol. 198:1274-1284(2017). RN [63] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION). RX PubMed=28848048; DOI=10.1074/jbc.m117.805127; RA Ning Y.J., Feng K., Min Y.Q., Deng F., Hu Z., Wang H.; RT "Heartland virus NSs protein disrupts host defenses by blocking the TBK1 RT kinase-IRF3 transcription factor interaction and signaling required for RT interferon induction."; RL J. Biol. Chem. 292:16722-16733(2017). RN [64] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION), INTERACTION RP WITH SFTSV NSS (MICROBIAL INFECTION), AND PHOSPHORYLATION AT SER-172. RX PubMed=28680969; DOI=10.1128/msphere.00234-17; RA Rezelj V.V., Li P., Chaudhary V., Elliott R.M., Jin D.Y., Brennan B.; RT "Differential Antagonism of Human Innate Immune Responses by Tick-Borne RT Phlebovirus Nonstructural Proteins."; RL MSphere 2:0-0(2017). RN [65] RP INTERACTION WITH TRIM23. RX PubMed=28871090; DOI=10.1038/s41564-017-0017-2; RA Sparrer K.M.J., Gableske S., Zurenski M.A., Parker Z.M., Full F., RA Baumgart G.J., Kato J., Pacheco-Rodriguez G., Liang C., Pornillos O., RA Moss J., Vaughan M., Gack M.U.; RT "TRIM23 mediates virus-induced autophagy via activation of TBK1."; RL Nat. Microbiol. 2:1543-1557(2017). RN [66] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=28904192; DOI=10.1128/jvi.01156-17; RA Manivanh R., Mehrbach J., Knipe D.M., Leib D.A.; RT "Role of Herpes Simplex Virus 1 gamma34.5 in the Regulation of IRF3 RT Signaling."; RL J. Virol. 91:0-0(2017). RN [67] RP INTERACTION WITH ZIKA VIRUS NON-STRUCTURAL PROTEIN 1 AND NON-STRUCTURAL RP PROTEIN 4B (MICROBIAL INFECTION). RX PubMed=28373913; DOI=10.1038/celldisc.2017.6; RA Wu Y., Liu Q., Zhou J., Xie W., Chen C., Wang Z., Yang H., Cui J.; RT "Zika virus evades interferon-mediated antiviral response through the co- RT operation of multiple nonstructural proteins in vitro."; RL Cell Discov. 3:17006-17006(2017). RN [68] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [69] RP INTERACTION WITH CEP170. RX PubMed=30354798; DOI=10.1091/mbc.e18-02-0115; RA Baerenz F., Kschonsak Y.T., Meyer A., Jafarpour A., Lorenz H., Hoffmann I.; RT "Ccdc61 controls centrosomal localization of Cep170 and is required for RT spindle assembly and symmetry."; RL Mol. Biol. Cell 29:3105-3118(2018). RN [70] RP INTERACTION WITH TTC4; IKBKE; AZI2 AND TANK, AND SUBCELLULAR LOCATION. RX PubMed=29251827; DOI=10.1002/pmic.201700403; RA Shang J., Xia T., Han Q.Q., Zhao X., Hu M.M., Shu H.B., Guo L.; RT "Quantitative Proteomics Identified TTC4 as a TBK1 Interactor and a RT Positive Regulator of SeV-Induced Innate Immunity."; RL Proteomics 18:0-0(2018). RN [71] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=30021900; DOI=10.1128/jvi.00706-18; RA Moriyama M., Igarashi M., Koshiba T., Irie T., Takada A., Ichinohe T.; RT "Two Conserved Amino Acids within the NSs of Severe Fever with RT Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon RT Activity."; RL J. Virol. 92:0-0(2018). RN [72] RP INTERACTION WITH HNRNPA2B1. RX PubMed=31320558; DOI=10.1126/science.aav0758; RA Wang L., Wen M., Cao X.; RT "Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to RT DNA viruses."; RL Science 0:0-0(2019). RN [73] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31530866; DOI=10.1038/s41598-019-49707-8; RA Antonia R.J., Castillo J., Herring L.E., Serafin D.S., Liu P., Graves L.M., RA Baldwin A.S., Hagan R.S.; RT "TBK1 limits mTORC1 by promoting phosphorylation of Raptor Ser877."; RL Sci. Rep. 9:13470-13470(2019). RN [74] RP INTERACTION WITH RNF144B. RX PubMed=31509299; DOI=10.1002/jlb.2a0819-055r; RA Zhang Z., Zhang L., Wang B., Zhu X., Zhao L., Chu C., Guo Q., Wei R., RA Yin X., Zhang Y., Li X.; RT "RNF144B inhibits LPS-induced inflammatory responses via binding TBK1."; RL J. Leukoc. Biol. 106:1303-1311(2019). RN [75] RP INTERACTION WITH CYLD. RX PubMed=32185393; DOI=10.1093/brain/awaa039; RA Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G., RA Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T., RA Thompson E.M., Blumbergs P., Short C.L., Field C.D., Panegyres P.K., RA Hecker J., Nicholson G., Shaw A.D., Fullerton J.M., Luty A.A., RA Schofield P.R., Brooks W.S., Rajan N., Bennett M.F., Bahlo M., RA Landers J.E., Piguet O., Hodges J.R., Halliday G.M., Topp S.D., Smith B.N., RA Shaw C.E., McCann E., Fifita J.A., Williams K.L., Atkin J.D., Blair I.P., RA Kwok J.B.; RT "CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral RT sclerosis."; RL Brain 143:783-799(2020). RN [76] RP INTERACTION WITH SARS-COV-2 NON-STRUCTURAL PROTEIN 6 (MICROBIAL INFECTION), RP AND INTERACTION WITH SARS-COV-2 HELICASE (MICROBIAL INFECTION). RX PubMed=32979938; DOI=10.1016/j.celrep.2020.108234; RA Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D., RA Rajsbaum R., Shi P.Y.; RT "Evasion of Type I Interferon by SARS-CoV-2."; RL Cell Rep. 33:108234-108234(2020). RN [77] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31709703; DOI=10.15252/embr.201948317; RA Herhaus L., Bhaskara R.M., Lystad A.H., Gestal-Mato U., RA Covarrubias-Pinto A., Bonn F., Simonsen A., Hummer G., Dikic I.; RT "TBK1-mediated phosphorylation of LC3C and GABARAP-L2 controls RT autophagosome shedding by ATG4 protease."; RL EMBO Rep. 21:e48317-e48317(2020). RN [78] RP INTERACTION WITH TRIM14, AND FUNCTION. RX PubMed=32404352; DOI=10.4049/jimmunol.1901511; RA Hoffpauir C.T., Bell S.L., West K.O., Jing T., Wagner A.R., Torres-Odio S., RA Cox J.S., West A.P., Li P., Patrick K.L., Watson R.O.; RT "TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium RT tuberculosis Infection."; RL J. Immunol. 205:153-167(2020). RN [79] RP INTERACTION WITH TAX1BP1. RX PubMed=33226137; DOI=10.15252/embj.2020104948; RA Ohnstad A.E., Delgado J.M., North B.J., Nasa I., Kettenbach A.N., RA Schultz S.W., Shoemaker C.J.; RT "Receptor-mediated clustering of FIP200 bypasses the role of LC3 lipidation RT in autophagy."; RL EMBO J. 39:e104948-e104948(2020). RN [80] RP INTERACTION WITH TRAF3IP3, AND UBIQUITINATION. RX PubMed=32366851; DOI=10.1038/s41467-020-16014-0; RA Deng M., Tam J.W., Wang L., Liang K., Li S., Zhang L., Guo H., Luo X., RA Zhang Y., Petrucelli A., Davis B.K., Conti B.J., June Brickey W., Ko C.C., RA Lei Y.L., Sun S., Ting J.P.; RT "TRAF3IP3 negatively regulates cytosolic RNA induced anti-viral signaling RT by promoting TBK1 K48 ubiquitination."; RL Nat. Commun. 11:2193-2193(2020). RN [81] RP INTERACTION WITH IKBKB. RX PubMed=32209697; DOI=10.1126/scisignal.aay0574; RA Metwally H., Tanaka T., Li S., Parajuli G., Kang S., Hanieh H., RA Hashimoto S., Chalise J.P., Gemechu Y., Standley D.M., Kishimoto T.; RT "Noncanonical STAT1 phosphorylation expands its transcriptional activity RT into promoting LPS-induced IL-6 and IL-12p40 production."; RL Sci. Signal. 13:0-0(2020). RN [82] RP INTERACTION WITH SARS-COV-2 M PROTEIN (MICROBIAL INFECTION), FUNCTION, AND RP UBIQUITINATION. RX PubMed=34084167; DOI=10.3389/fimmu.2021.662989; RA Sui L., Zhao Y., Wang W., Wu P., Wang Z., Yu Y., Hou Z., Tan G., Liu Q.; RT "SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through RT Ubiquitin-Mediated Degradation of TBK1."; RL Front. Immunol. 12:662989-662989(2021). RN [83] RP INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL35 (MICROBIAL INFECTION). RX PubMed=32466380; DOI=10.3390/microorganisms8060790; RA Fabits M., Goncalves Magalhaes V., Chan B., Girault V., Elbasani E., RA Rossetti E., Saeland E., Messerle M., Pichlmair A., Lisnic V.J., RA Brinkmann M.M.; RT "The Cytomegalovirus Tegument Protein UL35 Antagonizes Pattern Recognition RT Receptor-Mediated Type I IFN Transcription."; RL Microorganisms 8:0-0(2020). RN [84] RP FUNCTION, INTERACTION WITH ASB8, AND SUBCELLULAR LOCATION. RX PubMed=32298923; DOI=10.1016/j.molimm.2020.03.011; RA Guo Y., Li R., Tan Z., Shi J., Fu Y., Song Y., Zhu M., Zhang L., Huang J.; RT "E3 ubiquitin ligase ASB8 negatively regulates interferon via regulating RT TBK1/IKKi homeostasis."; RL Mol. Immunol. 121:195-203(2020). RN [85] RP UBIQUITINATION BY TRAF7. RX PubMed=37086853; DOI=10.1016/j.virs.2023.04.005; RA Huang J.P., Yang Y.X., Chen T., Wang D.D., Li J., Xu L.G.; RT "TRAF7 negatively regulates the RLR signaling pathway by facilitating the RT K48-linked ubiquitination of TBK1."; RL Virol. Sin. 38:419-428(2023). RN [86] RP DEUBIQUITINATION BY EPSTEIN-BARR VIRUS PROTEIN BPLF1 (MICROBIAL INFECTION). RX PubMed=36802409; DOI=10.1371/journal.ppat.1011186; RA Lui W.Y., Bharti A., Wong N.M., Jangra S., Botelho M.G., Yuen K.S., RA Jin D.Y.; RT "Suppression of cGAS- and RIG-I-mediated innate immune signaling by RT Epstein-Barr virus deubiquitinase BPLF1."; RL PLoS Pathog. 19:e1011186-e1011186(2023). RN [87] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, HOMODIMER, UBIQUITINATION AT LYS-30 AND LYS-401, AND RP MUTAGENESIS OF LYS-30; ASP-33; LYS-38; ASP-135; GLU-355; ARG-357; LYS-401; RP ARG-547; TYR-577; GLU-580; ILE-582 AND LYS-589. RX PubMed=23453971; DOI=10.1016/j.celrep.2013.01.034; RA Larabi A., Devos J.M., Ng S.L., Nanao M.H., Round A., Maniatis T., RA Panne D.; RT "Crystal structure and mechanism of activation of TANK-binding kinase 1."; RL Cell Rep. 3:734-746(2013). RN [88] RP X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, AUTOPHOSPHORYLATION, HOMODIMER, INTERACTION WITH RP AZI2, AND MUTAGENESIS OF LYS-38; ASP-135; SER-172; LEU-316; TYR-325; RP GLU-355; GLU-448; HIS-459; ILE-466 AND PHE-470. RX PubMed=23453972; DOI=10.1016/j.celrep.2013.01.033; RA Tu D., Zhu Z., Zhou A.Y., Yun C.H., Lee K.E., Toms A.V., Li Y., Dunn G.P., RA Chan E., Thai T., Yang S., Ficarro S.B., Marto J.A., Jeon H., Hahn W.C., RA Barbie D.A., Eck M.J.; RT "Structure and ubiquitination-dependent activation of TANK-binding kinase RT 1."; RL Cell Rep. 3:747-758(2013). RN [89] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, AND PHOSPHORYLATION AT SER-172. RX PubMed=23746807; DOI=10.1016/j.str.2013.04.025; RA Shu C., Sankaran B., Chaton C.T., Herr A.B., Mishra A., Peng J., Li P.; RT "Structural insights into the functions of TBK1 in innate antimicrobial RT immunity."; RL Structure 21:1137-1148(2013). RN [90] RP STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF 1-729 OF MUTANT ASN-135 RP IN COMPLEX WITH STING1, FUNCTION, INTERACTION WITH STING1, ACTIVE SITE, AND RP MUTAGENESIS OF TYR-577; ASN-578 AND GLN-581. RX PubMed=30842653; DOI=10.1038/s41586-019-1000-2; RA Zhang C., Shang G., Gui X., Zhang X., Bai X.C., Chen Z.J.; RT "Structural basis of STING binding with and phosphorylation by TBK1."; RL Nature 567:394-398(2019). RN [91] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-271; GLU-291; HIS-296; ARG-410 AND RP ALA-464. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [92] RP VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; SER-388; RP THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, CHARACTERIZATION RP OF VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; RP SER-388; THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, AND RP FUNCTION. RX PubMed=32972995; DOI=10.1126/science.abd4570; RG COVID-STORM Clinicians; RG COVID Clinicians; RG Imagine COVID Group; RG French COVID Cohort Study Group; RG CoV-Contact Cohort; RG Amsterdam UMC Covid-19 Biobank; RG COVID Human Genetic Effort; RG NIAID-USUHS/TAGC COVID Immunity Group; RA Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., RA Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K., RA Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y., RA Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L., RA Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.H., RA Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P., RA Neehus A.L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F., RA Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlueter A., Le Voyer T., RA Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F., RA Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z., RA Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A., RA Bettini L.R., D'Angio' M., Bonfanti P., Imberti L., Sottini A., Paghera S., RA Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C., RA Vandernoot I., Goffard J.C., Smits G., Migeotte I., Haerynck F., RA Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.E., Keles S., RA Coelkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela S.N., RA Rodriguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y., RA Duval X., Laouenan C., Snow A.L., Dalgard C.L., Milner J.D., Vinh D.C., RA Mogensen T.H., Marr N., Spaan A.N., Boisson B., Boisson-Dupuis S., RA Bustamante J., Puel A., Ciancanelli M.J., Meyts I., Maniatis T., RA Soumelis V., Amara A., Nussenzweig M., Garcia-Sastre A., Krammer F., RA Pujol A., Duffy D., Lifton R.P., Zhang S.Y., Gorochov G., Beziat V., RA Jouanguy E., Sancho-Shimizu V., Rice C.M., Abel L., Notarangelo L.D., RA Cobat A., Su H.C., Casanova J.L.; RT "Inborn errors of type I IFN immunity in patients with life-threatening RT COVID-19."; RL Science 370:0-0(2020). RN [93] RP VARIANTS AIARV ASP-212; 440-ARG--LEU-729 DEL AND 619-TRP--LEU-729 DEL, RP CHARACTERIZATION OF VARIANTS AIARV ASP-212 AND 619-TRP--LEU-729 DEL, RP INVOLVEMENT IN AIARV, AND FUNCTION. RX PubMed=34363755; DOI=10.1016/j.cell.2021.07.026; RA Taft J., Markson M., Legarda D., Patel R., Chan M., Malle L., RA Richardson A., Gruber C., Martin-Fernandez M., Mancini G.M.S., RA van Laar J.A.M., van Pelt P., Buta S., Wokke B.H.A., Sabli I.K.D., RA Sancho-Shimizu V., Chavan P.P., Schnappauf O., Khubchandani R., RA Cueceoglu M.K., Oezen S., Kastner D.L., Ting A.T., Aksentijevich I., RA Hollink I.H.I.M., Bogunovic D.; RT "Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell RT death."; RL Cell 184:4447-4463.e20(2021). RN [94] RP VARIANT AIARV 440-ARG--LEU-729 DEL. RX PubMed=32447396; DOI=10.1093/rheumatology/keaa165; RA Kosukcu C., Taskiran E.Z., Batu E.D., Sag E., Bilginer Y., Alikasifoglu M., RA Ozen S.; RT "Whole exome sequencing in unclassified autoinflammatory diseases: more RT monogenic diseases in the pipeline?"; RL Rheumatology 60:607-616(2021). RN [95] RP FUNCTION, HOMODIMERIZATION, INTERACTION WITH IRF3; MAVS AND ZNF268, RP METHYLATION AT LYS-607, AND MUTAGENESIS OF LYS-584 AND LYS-607. RX PubMed=37926288; DOI=10.1016/j.jbc.2023.105428; RA Liu Y., Yin W., Zeng X., Fan J., Liu C., Gao M., Huang Z., Sun G., Guo M.; RT "TBK1-stabilized ZNF268a recruits SETD4 to methylate TBK1 for efficient RT interferon signaling."; RL J. Biol. Chem. 299:105428-105428(2023). CC -!- FUNCTION: Serine/threonine kinase that plays an essential role in CC regulating inflammatory responses to foreign agents (PubMed:10581243, CC PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, CC PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, CC PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, CC PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). CC Following activation of toll-like receptors by viral or bacterial CC components, associates with TRAF3 and TANK and phosphorylates CC interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X CC (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, CC PubMed:18583960, PubMed:25636800). This activity allows subsequent CC homodimerization and nuclear translocation of the IRFs leading to CC transcriptional activation of pro-inflammatory and antiviral genes CC including IFNA and IFNB (PubMed:12702806, PubMed:15367631, CC PubMed:25636800, PubMed:32972995). In order to establish such an CC antiviral state, TBK1 form several different complexes whose CC composition depends on the type of cell and cellular stimuli CC (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role CC in IRF3 activation: acts by first phosphorylating innate adapter CC proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to CC recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 CC (PubMed:25636800, PubMed:30842653, PubMed:37926288). Phosphorylated CC IRF3 dissociates from the adapter proteins, dimerizes, and then enters CC the nucleus to induce expression of interferons (PubMed:25636800). CC Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, CC TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing- CC complexes (PubMed:21931631). Under particular conditions, functions as CC a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor CC alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus CC (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation CC by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', CC thus enhancing LC3 binding affinity and antibacterial autophagy CC (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 CC complex, promoting autophagosome maturation (PubMed:27103069). CC Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing CC their delipidation and premature removal from nascent autophagosomes CC (PubMed:31709703). Seems to play a role in energy balance regulation by CC sustaining a state of chronic, low-grade inflammation in obesity, which CC leads to a negative impact on insulin sensitivity (By similarity). CC Attenuates retroviral budding by phosphorylating the endosomal sorting CC complex required for transport-I (ESCRT-I) subunit VPS37C CC (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein CC (PubMed:16155125). Plays an essential role in the TLR3- and IFN- CC dependent control of herpes virus HSV-1 and HSV-2 infections in the CC central nervous system (PubMed:22851595). Acts both as a positive and CC negative regulator of the mTORC1 complex, depending on the context: CC activates mTORC1 in response to growth factors by catalyzing CC phosphorylation of MTOR, while it limits the mTORC1 complex by CC promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). CC Acts as a positive regulator of the mTORC2 complex by mediating CC phosphorylation of MTOR, leading to increased phosphorylation and CC activation of AKT1 (By similarity). Phosphorylates and activates AKT1 CC (PubMed:21464307). Involved in the regulation of TNF-induced RIPK1- CC mediated cell death, probably acting via CYLD phosphorylation that in CC turn controls RIPK1 ubiquitination status (PubMed:34363755). Also CC participates in the differentiation of T follicular regulatory cells CC together with the receptor ICOS (PubMed:27135603). CC {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, CC ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, CC ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, CC ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, CC ECO:0000269|PubMed:27135603, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, CC ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:34363755, CC ECO:0000269|PubMed:37926288}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800}; CC -!- SUBUNIT: Homodimer (PubMed:21145761, PubMed:37926288). Interacts with CC DDX3X, TIRAP and TRAF2 (PubMed:10581243, PubMed:14530355). Part of a CC ternary complex consisting of TANK, TRAF2 and TBK1 (PubMed:10581243). CC Interacts with AZI2, TANK and TBKBP1; these interactions are mutually CC exclusive and mediate TBK1 activation (PubMed:10581243, CC PubMed:14560022, PubMed:21931631, PubMed:23453972, PubMed:29251827). CC Interacts with GSK3B; this interaction promotes TBK1 self-association CC and autophosphorylation (PubMed:21145761). Interacts with SIKE1; SIKE1 CC is associated with TBK1 under physiological condition and dissociated CC from TBK1 upon viral infection or TLR3 stimulation (PubMed:16281057). CC Interacts with IRF3, leading to IRF3 phosphorylation (PubMed:14703513, CC PubMed:25636800, PubMed:37926288). Interacts with RIGI CC (PubMed:16281057). Interacts with CYLD (PubMed:18636086, CC PubMed:32185393). Interacts with OPTN and TRAF3 (PubMed:20174559). CC Interacts with SRC (PubMed:19419966). Interacts with the exocyst CC complex subunit SEC5/EXOC2; this interaction is sufficient to trigger CC TBK1 activity (PubMed:17018283). Interacts with STING1, leading to CC STING1 phosphorylation (PubMed:19416887, PubMed:25636800, CC PubMed:30842653). Interacts with IFIT3 (via N-terminus) CC (PubMed:21813773). Interacts with MAVS; interaction only takes place in CC the presence of IFIT3 and leads to MAVS phosphorylation CC (PubMed:21813773, PubMed:25636800, PubMed:28011935, PubMed:37926288). CC Interacts (via protein kinase domain) with TTLL12 (via TTL domain); the CC interaction prevents MAVS binding to TBK1 (PubMed:28011935). Interacts CC with TICAM1; this interaction is enhanced in the presence of WDFY1 and CC leads to TICAM1 phosphorylation (PubMed:14530355, PubMed:14739303, CC PubMed:25636800, PubMed:25736436). Interacts with TRIM26 CC (PubMed:26611359). Interacts with TRIM23 (PubMed:28871090). Interacts CC with TTC4 and IKBKE (PubMed:29251827). Interacts with HNRNPA2B1 CC (PubMed:31320558). Interacts with DDX3X (PubMed:20375222). Interacts CC with TRIM14 (PubMed:32404352). Interacts with CEP170; efficient complex CC formation may be dependent on the presence of CCDC61 (PubMed:30354798). CC Interacts with TRAF3IP3 (PubMed:32366851). Interacts with HSP90AA1; the CC interaction mediates TBK1 association with TOMM70 (PubMed:20628368). CC Interacts with TAX1BP1 (PubMed:33226137). Interacts with kinase IKBKB; CC the complex interacts with STAT1, leading to phosphorylation of STAT1 CC on 'Thr-749' by IKBKB (PubMed:32209697). Interacts with ICOS; this CC interaction is critical for the maturation of T follicular regulatory CC cells (PubMed:27135603). Interacts with RNF144B; this interaction CC prevents TBK1 phosphorylation and subsequent activation CC (PubMed:31509299). Interacts with ASB8; this interaction promotes TBK1 CC proteasomal degradation (PubMed:32298923). Forms a ternary complex with CC ZNF268 and SETD4; the interaction with SETD4 is ZNF268-dependent and CC leads to TBK1 monomethylation, which enhances its interaction with IRF3 CC and MAVS (PubMed:37926288). {ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:14530355, ECO:0000269|PubMed:14560022, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:14739303, CC ECO:0000269|PubMed:16281057, ECO:0000269|PubMed:17018283, CC ECO:0000269|PubMed:18636086, ECO:0000269|PubMed:19416887, CC ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20174559, CC ECO:0000269|PubMed:20375222, ECO:0000269|PubMed:20628368, CC ECO:0000269|PubMed:21145761, ECO:0000269|PubMed:21813773, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27135603, CC ECO:0000269|PubMed:28011935, ECO:0000269|PubMed:28871090, CC ECO:0000269|PubMed:29251827, ECO:0000269|PubMed:30354798, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31320558, CC ECO:0000269|PubMed:31509299, ECO:0000269|PubMed:32185393, CC ECO:0000269|PubMed:32209697, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:32404352, CC ECO:0000269|PubMed:33226137, ECO:0000269|PubMed:37926288}. CC -!- SUBUNIT: (Microbial infection) Interacts with Borna disease virus (BDV) CC P protein leading to its phosphorylation. CC {ECO:0000269|PubMed:16155125}. CC -!- SUBUNIT: (Microbial infection) Interacts with Ebola virus protein VP35. CC {ECO:0000269|PubMed:19153231}. CC -!- SUBUNIT: (Microbial infection) Interacts with HCV NS3; this interaction CC leads to inhibition of cellular antiviral response by blocking CC necessary interactions between the TBK1 and its substrates IRF3 and CC IRF7. {ECO:0000269|PubMed:15841462}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 1 CC protein ICP34.5. {ECO:0000269|PubMed:19010780, CC ECO:0000269|PubMed:28904192}. CC -!- SUBUNIT: (Microbial infection) Interacts with Zika virus non-structural CC protein 1/NS1 and non-structural protein 4B/NS4B. CC {ECO:0000269|PubMed:28373913}. CC -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV-2 non-structural CC protein 6; this interaction decreases IRF3 phosphorylation by 57%, CC which leads to reduced IFN-beta (IFNB) production (PubMed:32979938). CC Interacts with SARS-CoV-2 helicase; this interaction inhibits TBK1 CC phosphorylation and decreases IRF3 phosphorylation by 75%, which leads CC to reduced IFN-beta production (PubMed:32979938). Interacts with SARS- CC CoV-2 M protein; the interaction promotes TBK1 degradation via 'Lys- CC 48'-linked ubiquitination (PubMed:34084167). CC {ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:34084167}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC protein UL35; this interaction inhibits type I interferon production. CC {ECO:0000269|PubMed:32466380}. CC -!- SUBUNIT: (Microbial infection) Interacts with heartland virus NSs; this CC interaction antagonizes TBK1 phosphorylation and inhibits TBK1-IRF3 CC interaction and thus the establishment of an antiviral state. CC {ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:28848048}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with Severe CC fever with thrombocytopenia virus (SFTSV) NSs; this interaction CC antagonizes TBK1 phosphorylation and sequesters TBK1 in NSs-induced CC cytoplasmic inclusion bodies thereby inhibiting the IFN responses. CC {ECO:0000269|PubMed:24478431, ECO:0000269|PubMed:24706939, CC ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:30021900}. CC -!- INTERACTION: CC Q9UHD2; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-356402, EBI-528269; CC Q9UHD2; Q7Z3C6: ATG9A; NbExp=2; IntAct=EBI-356402, EBI-727146; CC Q9UHD2; Q9H6S1: AZI2; NbExp=7; IntAct=EBI-356402, EBI-359973; CC Q9UHD2; Q13137: CALCOCO2; NbExp=10; IntAct=EBI-356402, EBI-739580; CC Q9UHD2; Q6DT37: CDC42BPG; NbExp=3; IntAct=EBI-356402, EBI-689124; CC Q9UHD2; P08238: HSP90AB1; NbExp=3; IntAct=EBI-356402, EBI-352572; CC Q9UHD2; Q9Y6W8: ICOS; NbExp=5; IntAct=EBI-356402, EBI-3922712; CC Q9UHD2; Q14164: IKBKE; NbExp=5; IntAct=EBI-356402, EBI-307369; CC Q9UHD2; Q9Y6K9: IKBKG; NbExp=6; IntAct=EBI-356402, EBI-81279; CC Q9UHD2; Q14653: IRF3; NbExp=10; IntAct=EBI-356402, EBI-2650369; CC Q9UHD2; Q92985: IRF7; NbExp=2; IntAct=EBI-356402, EBI-968267; CC Q9UHD2; Q9H492: MAP1LC3A; NbExp=2; IntAct=EBI-356402, EBI-720768; CC Q9UHD2; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-356402, EBI-373144; CC Q9UHD2; Q7Z434: MAVS; NbExp=6; IntAct=EBI-356402, EBI-995373; CC Q9UHD2; Q86YT6: MIB1; NbExp=2; IntAct=EBI-356402, EBI-2129148; CC Q9UHD2; Q96AX9: MIB2; NbExp=2; IntAct=EBI-356402, EBI-2130249; CC Q9UHD2; Q9NVV4: MTPAP; NbExp=2; IntAct=EBI-356402, EBI-2556166; CC Q9UHD2; Q96CV9: OPTN; NbExp=17; IntAct=EBI-356402, EBI-748974; CC Q9UHD2; O14730: RIOK3; NbExp=3; IntAct=EBI-356402, EBI-1047061; CC Q9UHD2; P42226: STAT6; NbExp=7; IntAct=EBI-356402, EBI-1186478; CC Q9UHD2; Q86WV6: STING1; NbExp=9; IntAct=EBI-356402, EBI-2800345; CC Q9UHD2; O75558: STX11; NbExp=5; IntAct=EBI-356402, EBI-714135; CC Q9UHD2; Q92844: TANK; NbExp=15; IntAct=EBI-356402, EBI-356349; CC Q9UHD2; Q9UHD2: TBK1; NbExp=2; IntAct=EBI-356402, EBI-356402; CC Q9UHD2; A7MCY6: TBKBP1; NbExp=9; IntAct=EBI-356402, EBI-359969; CC Q9UHD2; Q8IUC6: TICAM1; NbExp=3; IntAct=EBI-356402, EBI-525995; CC Q9UHD2; Q12933: TRAF2; NbExp=9; IntAct=EBI-356402, EBI-355744; CC Q9UHD2; Q13114: TRAF3; NbExp=4; IntAct=EBI-356402, EBI-357631; CC Q9UHD2; O95801: TTC4; NbExp=5; IntAct=EBI-356402, EBI-1050890; CC Q9UHD2; P40222: TXLNA; NbExp=8; IntAct=EBI-356402, EBI-359793; CC Q9UHD2; Q62167: Ddx3x; Xeno; NbExp=8; IntAct=EBI-356402, EBI-773173; CC Q9UHD2; O41932: GAMMAHV.ORF11; Xeno; NbExp=4; IntAct=EBI-356402, EBI-9544132; CC Q9UHD2; P0DTC5: M; Xeno; NbExp=10; IntAct=EBI-356402, EBI-25475853; CC Q9UHD2; P59596: M; Xeno; NbExp=5; IntAct=EBI-356402, EBI-25487824; CC Q9UHD2; W5VXH5: NSs; Xeno; NbExp=3; IntAct=EBI-356402, EBI-9543922; CC Q9UHD2; PRO_0000449630 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-356402, EBI-25475888; CC Q9UHD2; Q60803: Traf3; Xeno; NbExp=2; IntAct=EBI-356402, EBI-520135; CC Q9UHD2; Q8BHN1: Txlng; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6116854; CC Q9UHD2; Q05127: VP35; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6148294; CC Q9UHD2; I6W9F2; Xeno; NbExp=6; IntAct=EBI-356402, EBI-9518472; CC Q9UHD2; K7Y1A2; Xeno; NbExp=2; IntAct=EBI-356402, EBI-8788634; CC Q9UHD2; PRO_0000037572 [P27958]; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6919131; CC Q9UHD2; PRO_0000037573 [P27958]; Xeno; NbExp=4; IntAct=EBI-356402, EBI-3649474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15485837, CC ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:29251827, CC ECO:0000269|PubMed:32298923}. Note=Upon mitogen stimulation or CC triggering of the immune system, TBK1 is recruited to the exocyst by CC EXOC2. {ECO:0000269|PubMed:17018283}. CC -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in testis. CC Expressed in the ganglion cells, nerve fiber layer and microvasculature CC of the retina. {ECO:0000269|PubMed:10783893, CC ECO:0000269|PubMed:21447600}. CC -!- DOMAIN: Comprises A N-terminal kinase domain, a ubiquitin-like domain CC and a C-terminal coiled-coil region mediating homodimerization. CC {ECO:0000269|PubMed:17599067, ECO:0000269|PubMed:21042276}. CC -!- PTM: Autophosphorylation at Ser-172 activates the kinase, and is an CC essential step for virus-triggered signaling. Phosphorylated by CC IKBKB/IKKB at Ser-172. Phosphorylation requires homodimerization and CC ubiquitination at Lys-30 and Lys-401. Dephosphorylated at Ser-172 by CC PPM1B and this negatively regulates its role in mediating antiviral CC response. {ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:21138416, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23746807}. CC -!- PTM: 'Lys-63'-linked polyubiquitination by MIB1 after RNA virus CC infection, or by NRDP1 after LPS stimulation at Lys-30 and Lys-401, CC participates in kinase activation. 'Lys-48'-linked polyubiquitination CC at Lys-670 by DTX4 leads to proteasomal degradation. 'Lys-48'-linked CC polyubiquitination by TRAIP also leads to proteasomal degradation. CC 'Lys-48'-linked polyubiquitination by TRAF7; leading to proteasomal CC degradation (PubMed:37086853). 'Lys-63'-linked polyubiquitination by CC RNF128 at Lys-30 and Lys-401 leads to the activation of antiviral CC responses. 'Lys-48'-linked polyubiquitination after 'lys-33'-linked CC deubiquitination by USP38 promotes TBK1 degradation (PubMed:27692986). CC {ECO:0000269|PubMed:22388039, ECO:0000269|PubMed:23453971, CC ECO:0000269|PubMed:27692986, ECO:0000269|PubMed:27776110, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:37086853}. CC -!- PTM: (Microbial infection) Interaction with SARS-CoV-2 M protein CC induces 'Lys-48'-linked ubiquitination which leads to proteasomal CC degradation. {ECO:0000269|PubMed:34084167}. CC -!- PTM: (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1 CC on both 'Lys-48' and 'Lys-63'-linked ubiquitin chains; leading to CC inhibition of type I interfewron production. CC {ECO:0000269|PubMed:36802409}. CC -!- PTM: Monomethylation at Lys-607 by SETD4 maximizes TBK1 activation and CC promotes efficient interferon signaling. {ECO:0000269|PubMed:37926288}. CC -!- DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of CC primary open angle glaucoma (POAG). POAG is characterized by a specific CC pattern of optic nerve and visual field defects. The angle of the CC anterior chamber of the eye is open, and usually the intraocular CC pressure is increased. However, glaucoma can occur at any intraocular CC pressure. The disease is generally asymptomatic until the late stages, CC by which time significant and irreversible optic nerve damage has CC already taken place. GLC1P is characterized by early onset, thin CC central corneas and low intraocular pressure. CC {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. A copy number variation on chromosome 12q14 consisting of a CC 300 kb duplication that includes TBK1, XPOT, RASSF3 and GNS has been CC found in individuals affected by glaucoma. TBK1 is the most likely CC candidate for the disorder (PubMed:21447600). CC {ECO:0000269|PubMed:21447600}. CC -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 CC (FTDALS4) [MIM:616439]: A neurodegenerative disorder characterized by CC frontotemporal dementia and/or amyotrophic lateral sclerosis in CC affected individuals. There is high intrafamilial variation. CC Frontotemporal dementia is characterized by frontal and temporal lobe CC atrophy associated with neuronal loss, gliosis, and dementia. Patients CC exhibit progressive changes in social, behavioral, and/or language CC function. Amyotrophic lateral sclerosis is characterized by the death CC of motor neurons in the brain, brainstem, and spinal cord, resulting in CC fatal paralysis. {ECO:0000269|PubMed:25803835, CC ECO:0000269|PubMed:25943890}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Encephalopathy, acute, infection-induced, 8, herpes-specific CC (IIAE8) [MIM:617900]: A rare, often fatal complication of herpes CC simplex infection, caused by virus spreading in the central nervous CC system. Disease manifestations include low-grade fever, severe CC headache, nausea, vomiting, and lethargy. Neurological features include CC confusion, acute memory disturbances, disorientation, behavioral CC changes, hemiparesis and seizures. {ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:26513235}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Autoinflammation with arthritis and vasculitis (AIARV) CC [MIM:620880]: An autosomal recessive disorder characterized by onset of CC chronic and systemic autoinflammation in infancy or early childhood. CC Affected individuals have recurrent fever, erythematous skin rashes, CC vasculitis, oral aphthous lesions, and polyarthritis. Additional CC variable features are poor overall growth, microcytic anemia, mild CC intellectual disability, and seizures. {ECO:0000269|PubMed:32447396, CC ECO:0000269|PubMed:34363755}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In cancer cells, pathological TBK1 activation promotes CC oncogenic transformation by suppressing programmed cell death. CC Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade seems to CC participate in both innate immune signaling and cell transformation. CC Additionally, TBK1 supports oncogenesis by directly phosphorylating and CC activating AKT1 at the exocyst (PubMed:21042276). CC {ECO:0000305|PubMed:21042276}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. I-kappa-B kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92129.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF191838; AAF05989.1; -; mRNA. DR EMBL; AF174536; AAF69106.1; -; mRNA. DR EMBL; AK002192; BAA92129.1; ALT_INIT; mRNA. DR EMBL; AK291039; BAF83728.1; -; mRNA. DR EMBL; CH471054; EAW97133.1; -; Genomic_DNA. DR EMBL; BC034950; AAH34950.1; -; mRNA. DR CCDS; CCDS8968.1; -. DR RefSeq; NP_037386.1; NM_013254.4. DR RefSeq; XP_005268866.1; XM_005268809.2. DR RefSeq; XP_005268867.1; XM_005268810.2. DR RefSeq; XP_054227832.1; XM_054371857.1. DR RefSeq; XP_054227833.1; XM_054371858.1. DR PDB; 4EFO; X-ray; 1.77 A; A/B=302-383. DR PDB; 4EUT; X-ray; 2.60 A; A/B=2-385. DR PDB; 4EUU; X-ray; 1.80 A; A/B=2-308. DR PDB; 4IM0; X-ray; 2.40 A; A=1-657. DR PDB; 4IM2; X-ray; 2.50 A; A=1-657. DR PDB; 4IM3; X-ray; 3.34 A; A=1-657. DR PDB; 4IW0; X-ray; 4.00 A; A=2-657. DR PDB; 4IWO; X-ray; 2.61 A; A=2-657. DR PDB; 4IWP; X-ray; 3.06 A; A=2-657. DR PDB; 4IWQ; X-ray; 3.00 A; A=2-657. DR PDB; 5EOA; X-ray; 2.50 A; C/D=677-729. DR PDB; 5EOF; X-ray; 2.05 A; C/D=677-729. DR PDB; 5EP6; X-ray; 1.45 A; B/D=677-729. DR PDB; 5W5V; X-ray; 3.65 A; A=1-657. DR PDB; 6BNY; X-ray; 3.34 A; A=1-657. DR PDB; 6BOD; X-ray; 3.20 A; A=1-657. DR PDB; 6BOE; X-ray; 3.60 A; A=1-657. DR PDB; 6CQ0; X-ray; 3.19 A; A=1-657. DR PDB; 6CQ4; X-ray; 3.20 A; A=1-657. DR PDB; 6CQ5; X-ray; 3.35 A; A=1-657. DR PDB; 6NT9; EM; 3.30 A; A/B=1-729. DR PDB; 6O8B; X-ray; 3.40 A; A/B=2-657. DR PDB; 6RSR; X-ray; 3.15 A; A=2-657. DR PDB; 6RST; X-ray; 3.29 A; A=2-657. DR PDB; 6RSU; X-ray; 2.75 A; A=2-657. DR PDBsum; 4EFO; -. DR PDBsum; 4EUT; -. DR PDBsum; 4EUU; -. DR PDBsum; 4IM0; -. DR PDBsum; 4IM2; -. DR PDBsum; 4IM3; -. DR PDBsum; 4IW0; -. DR PDBsum; 4IWO; -. DR PDBsum; 4IWP; -. DR PDBsum; 4IWQ; -. DR PDBsum; 5EOA; -. DR PDBsum; 5EOF; -. DR PDBsum; 5EP6; -. DR PDBsum; 5W5V; -. DR PDBsum; 6BNY; -. DR PDBsum; 6BOD; -. DR PDBsum; 6BOE; -. DR PDBsum; 6CQ0; -. DR PDBsum; 6CQ4; -. DR PDBsum; 6CQ5; -. DR PDBsum; 6NT9; -. DR PDBsum; 6O8B; -. DR PDBsum; 6RSR; -. DR PDBsum; 6RST; -. DR PDBsum; 6RSU; -. DR AlphaFoldDB; Q9UHD2; -. DR EMDB; EMD-0506; -. DR SMR; Q9UHD2; -. DR BioGRID; 118878; 435. DR ComplexPortal; CPX-6018; STING-TRAF3-TBK1 complex. DR ComplexPortal; CPX-6038; TBK1-IKKepsilon-NAP1 complex. DR ComplexPortal; CPX-6089; TBK1-IKKepsilon-TANK complex. DR ComplexPortal; CPX-6090; TBK1-IKKepsilon-SINTBAD complex. DR CORUM; Q9UHD2; -. DR DIP; DIP-27529N; -. DR FunCoup; Q9UHD2; 4748. DR IntAct; Q9UHD2; 197. DR MINT; Q9UHD2; -. DR STRING; 9606.ENSP00000329967; -. DR BindingDB; Q9UHD2; -. DR ChEMBL; CHEMBL5408; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9UHD2; -. DR GuidetoPHARMACOLOGY; 2237; -. DR GlyGen; Q9UHD2; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHD2; -. DR MetOSite; Q9UHD2; -. DR PhosphoSitePlus; Q9UHD2; -. DR BioMuta; TBK1; -. DR DMDM; 74761953; -. DR CPTAC; CPTAC-2972; -. DR CPTAC; CPTAC-2973; -. DR CPTAC; CPTAC-910; -. DR CPTAC; CPTAC-911; -. DR jPOST; Q9UHD2; -. DR MassIVE; Q9UHD2; -. DR PaxDb; 9606-ENSP00000329967; -. DR PeptideAtlas; Q9UHD2; -. DR ProteomicsDB; 84323; -. DR Pumba; Q9UHD2; -. DR Antibodypedia; 16584; 631 antibodies from 46 providers. DR DNASU; 29110; -. DR YCharOS; Q9UHD2; Tested 11 antibodies from 6 manufacturers. DR Ensembl; ENST00000331710.10; ENSP00000329967.5; ENSG00000183735.12. DR Ensembl; ENST00000650790.1; ENSP00000498995.1; ENSG00000183735.12. DR GeneID; 29110; -. DR KEGG; hsa:29110; -. DR MANE-Select; ENST00000331710.10; ENSP00000329967.5; NM_013254.4; NP_037386.1. DR UCSC; uc001ssc.3; human. DR AGR; HGNC:11584; -. DR CIViC; 29110; 1 evidence item across 1 molecular profile. DR ClinPGx; PA36348; -. DR CTD; 29110; -. DR DisGeNET; 29110; -. DR GeneCards; TBK1; -. DR HGNC; HGNC:11584; TBK1. DR HPA; ENSG00000183735; Low tissue specificity. DR MalaCards; TBK1; -. DR MIM; 177700; phenotype. DR MIM; 604834; gene. DR MIM; 616439; phenotype. DR MIM; 617900; phenotype. DR MIM; 620880; phenotype. DR OpenTargets; ENSG00000183735; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 275872; Frontotemporal dementia with motor neuron disease. DR Orphanet; 1930; Herpes simplex virus encephalitis. DR VEuPathDB; HostDB:ENSG00000183735; -. DR eggNOG; KOG4250; Eukaryota. DR GeneTree; ENSGT00950000182937; -. DR HOGENOM; CLU_000288_101_1_1; -. DR InParanoid; Q9UHD2; -. DR OMA; WSADMPV; -. DR OrthoDB; 10013850at2759; -. DR PAN-GO; Q9UHD2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHD2; -. DR PathwayCommons; Q9UHD2; -. DR Reactome; R-HSA-1606341; IRF3 mediated activation of type 1 IFN. DR Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta. DR Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA. DR Reactome; R-HSA-3249367; STAT6-mediated induction of chemokines. DR Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-9008059; Interleukin-37 signaling. DR Reactome; R-HSA-9013973; TICAM1-dependent activation of IRF3/IRF7. DR Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway. DR Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation. DR Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling. DR Reactome; R-HSA-936964; Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE). DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-9824878; Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF7. DR Reactome; R-HSA-9828211; Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligation. DR SABIO-RK; Q9UHD2; -. DR SignaLink; Q9UHD2; -. DR SIGNOR; Q9UHD2; -. DR Agora; ENSG00000183735; -. DR BioGRID-ORCS; 29110; 34 hits in 1203 CRISPR screens. DR CD-CODE; 7F558BCC; STING phase-separator. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; TBK1; human. DR EvolutionaryTrace; Q9UHD2; -. DR GeneWiki; TANK-binding_kinase_1; -. DR GenomeRNAi; 29110; -. DR Pharos; Q9UHD2; Tchem. DR PRO; PR:Q9UHD2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9UHD2; protein. DR Bgee; ENSG00000183735; Expressed in colonic epithelium and 198 other cell types or tissues. DR ExpressionAtlas; Q9UHD2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:1902554; C:serine/threonine protein kinase complex; NAS:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0003676; F:nucleic acid binding; IEA:Ensembl. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; NAS:ProtInc. DR GO; GO:0019903; F:protein phosphatase binding; ISS:ARUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IDA:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0002218; P:activation of innate immune response; IDA:UniProt. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; TAS:UniProtKB. DR GO; GO:0140896; P:cGAS/STING signaling pathway; TAS:FlyBase. DR GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IDA:UniProt. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0051607; P:defense response to virus; NAS:ComplexPortal. DR GO; GO:0044565; P:dendritic cell proliferation; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; TAS:UniProtKB. DR GO; GO:0045087; P:innate immune response; IDA:UniProtKB. DR GO; GO:0016236; P:macroautophagy; TAS:Reactome. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProt. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEP:UniProtKB. DR GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL. DR GO; GO:0016239; P:positive regulation of macroautophagy; IDA:HGNC. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032481; P:positive regulation of type I interferon production; IDA:UniProt. DR GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032479; P:regulation of type I interferon production; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; TAS:UniProtKB. DR GO; GO:0061470; P:T follicular helper cell differentiation; IDA:UniProt. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt. DR GO; GO:0060337; P:type I interferon-mediated signaling pathway; NAS:ComplexPortal. DR CDD; cd13988; STKc_TBK1; 1. DR CDD; cd21954; TBK1_C; 1. DR CDD; cd17127; Ubl_TBK1; 1. DR FunFam; 1.10.510.10:FF:000100; inhibitor of nuclear factor kappa-B kinase subunit epsilon; 1. DR FunFam; 1.20.1270.420:FF:000001; Serine/threonine-protein kinase TBK1; 1. DR FunFam; 3.30.200.20:FF:000106; serine/threonine-protein kinase TBK1 isoform X1; 1. DR FunFam; 3.10.20.90:FF:000112; TANK binding kinase TBK1; 1. DR Gene3D; 1.20.1270.420; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051180; IKK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041309; TBK1_CC1. DR InterPro; IPR041087; TBK1_ULD. DR PANTHER; PTHR22969; IKB KINASE; 1. DR PANTHER; PTHR22969:SF14; SERINE_THREONINE-PROTEIN KINASE TBK1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF18394; TBK1_CCD1; 1. DR Pfam; PF18396; TBK1_ULD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Amyotrophic lateral sclerosis; Antiviral defense; KW ATP-binding; Coiled coil; Cytoplasm; Disease variant; Glaucoma; KW Host-virus interaction; Immunity; Innate immunity; Isopeptide bond; Kinase; KW Methylation; Neurodegeneration; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..729 FT /note="Serine/threonine-protein kinase TBK1" FT /id="PRO_0000086743" FT DOMAIN 9..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 309..385 FT /note="Ubiquitin-like" FT REGION 621..729 FT /note="Interaction with AZI2, TANK and TBKBP1" FT /evidence="ECO:0000269|PubMed:21931631" FT COILED 407..657 FT /evidence="ECO:0000250|UniProtKB:Q9WUN2" FT COILED 658..713 FT /evidence="ECO:0000255" FT ACT_SITE 135 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:23453971, FT ECO:0000305|PubMed:23453972, ECO:0000305|PubMed:30842653" FT BINDING 15..23 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 172 FT /note="Phosphoserine; by autocatalysis and IKKB" FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23746807" FT MOD_RES 607 FT /note="N6-methyllysine; by SETD4" FT /evidence="ECO:0000269|PubMed:37926288" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 30 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 401 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22388039, FT ECO:0000269|PubMed:27692986" FT VARIANT 24 FT /note="F -> S (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084111" FT VARIANT 47 FT /note="R -> H (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073938" FT VARIANT 50 FT /note="D -> A (in IIAE8; decreased expression levels; FT dbSNP:rs1010930015)" FT /evidence="ECO:0000269|PubMed:22851595" FT /id="VAR_080517" FT VARIANT 105 FT /note="Y -> C (in FTDALS4; dbSNP:rs1366668789)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073939" FT VARIANT 151 FT /note="S -> F (in dbSNP:rs55824172)" FT /evidence="ECO:0000269|PubMed:21447600" FT /id="VAR_069754" FT VARIANT 152 FT /note="V -> L (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084112" FT VARIANT 159 FT /note="G -> A (in IIAE8; loss of kinase activity; loss of FT autophosphorylation at S-172; loss of IFNB induction; FT dbSNP:rs1555202947)" FT /evidence="ECO:0000269|PubMed:22851595, FT ECO:0000269|PubMed:32972995" FT /id="VAR_080518" FT VARIANT 207 FT /note="I -> V (in IIAE8; uncertain significance; FT dbSNP:rs1555203557)" FT /evidence="ECO:0000269|PubMed:26513235" FT /id="VAR_080519" FT VARIANT 212 FT /note="Y -> D (in AIARV; likely pathogenic; severely FT decreased function in IRF3 phosphorylation and in positive FT regulation of type I interferon-mediated signaling pathway; FT does not rescue defective IRF3 phosphorylation on S-386 and FT IFN-1 stimulated gene expression in TBK1-deficient patient FT cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089908" FT VARIANT 271 FT /note="R -> Q (in dbSNP:rs56196591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041208" FT VARIANT 291 FT /note="K -> E (in dbSNP:rs34774243)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041209" FT VARIANT 296 FT /note="D -> H (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041210" FT VARIANT 305 FT /note="I -> T (in FTDALS4; dbSNP:rs770942184)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073940" FT VARIANT 306 FT /note="L -> I (in FTDALS4; uncertain significance; FT dbSNP:rs201970436)" FT /evidence="ECO:0000269|PubMed:21447600, FT ECO:0000269|PubMed:25943890" FT /id="VAR_069755" FT VARIANT 308..729 FT /note="Missing (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084113" FT VARIANT 308 FT /note="R -> Q (in FTDALS4; reduced kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073941" FT VARIANT 357 FT /note="R -> Q (in FTDALS4; reduced kinase activity; FT dbSNP:rs758357594)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073942" FT VARIANT 384 FT /note="R -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084114" FT VARIANT 388 FT /note="N -> D (in dbSNP:rs17857028)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024746" FT VARIANT 388 FT /note="N -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084115" FT VARIANT 397 FT /note="I -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084116" FT VARIANT 401 FT /note="K -> E (in FTDALS4; dbSNP:rs756751089)" FT /evidence="ECO:0000269|PubMed:25943890" FT /id="VAR_073943" FT VARIANT 410 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1262765773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041211" FT VARIANT 440..729 FT /note="Missing (in AIARV; pathogenic)" FT /evidence="ECO:0000269|PubMed:32447396, FT ECO:0000269|PubMed:34363755" FT /id="VAR_089909" FT VARIANT 464 FT /note="V -> A (in dbSNP:rs35635889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21447600" FT /id="VAR_041212" FT VARIANT 508 FT /note="L -> I (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084117" FT VARIANT 522 FT /note="I -> M (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084118" FT VARIANT 533 FT /note="A -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084119" FT VARIANT 559 FT /note="M -> R (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073944" FT VARIANT 570 FT /note="K -> Q (in dbSNP:rs17853341)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024747" FT VARIANT 571 FT /note="A -> V (in FTDALS4; dbSNP:rs765035140)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073945" FT VARIANT 598 FT /note="M -> V (in FTDALS4; dbSNP:rs899858451)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073946" FT VARIANT 619..729 FT /note="Missing (in AIARV; pathogenic; homozygous patient- FT derived cells show high rates of cell death; loss of FT protein expression in homozygous patient cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089910" FT VARIANT 643 FT /note="Missing (in FTDALS4)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073947" FT VARIANT 653 FT /note="E -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084120" FT VARIANT 659 FT /note="P -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084121" FT VARIANT 696 FT /note="E -> K (in FTDALS4; loss of kinase activity; impairs FT binding to OPTN; dbSNP:rs748112833)" FT /evidence="ECO:0000269|PubMed:25803835, FT ECO:0000269|PubMed:25943890" FT /id="VAR_073948" FT MUTAGEN 30 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-401." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 33 FT /note="D->A: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 38 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10581243, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:29150432, FT ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703" FT MUTAGEN 135 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:21931631, FT ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 172 FT /note="S->A: Loss of kinase activity. No effect on FT dimerization. Loss of USP38-mediated degradation." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:27692986" FT MUTAGEN 172 FT /note="S->E: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 316 FT /note="L->E: Decreases kinase activity. No effect on FT phosphorylation." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 325 FT /note="Y->E: Abolishes phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 355 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with A-357 or R- FT 448." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 357 FT /note="R->A: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 401 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-30." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 448 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 459 FT /note="H->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-466 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 466 FT /note="I->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 470 FT /note="F->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-466." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 547 FT /note="R->D: Decreases phosphorylation and kinase activity. FT Abolishes dimerization." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 577 FT /note="Y->A: Decreases kinase activity. Reduced FT phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 578 FT /note="N->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 580 FT /note="E->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 581 FT /note="Q->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 582 FT /note="I->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 584 FT /note="K->A: Decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 589 FT /note="K->D: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 607 FT /note="K->A,R: Attenuated homodimerization during Sendai FT virus infection; decreased interaction with IRF3 or MAVS; FT decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 670 FT /note="K->R: Abrogates both 'Lys-48'-linked and 'Lys-33'- FT linked ubiquitination." FT /evidence="ECO:0000269|PubMed:27692986" FT MUTAGEN 690 FT /note="M->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 693 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 694 FT /note="K->E: Strongly decreases interaction with TANK and FT TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 704 FT /note="L->A: Strongly decreases interaction with AZI2, TANK FT and TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 708 FT /note="N->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 711 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT STRAND 1..3 FT /evidence="ECO:0007829|PDB:6CQ0" FT STRAND 5..17 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 19..28 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 29..31 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 34..40 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 42..46 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 49..61 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 65..67 FT /evidence="ECO:0007829|PDB:4IWO" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 82..87 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 94..99 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 109..128 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 138..140 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 151..155 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 161..163 FT /evidence="ECO:0007829|PDB:4IWQ" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:4EUT" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:4EUT" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 182..188 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 202..216 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 227..229 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 231..240 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 247..250 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6NT9" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 271..284 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4IWP" FT TURN 289..291 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 305..307 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 308..315 FT /evidence="ECO:0007829|PDB:4EFO" FT TURN 316..319 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 320..327 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 332..343 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 347..349 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 350..354 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 375..377 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 379..383 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 408..480 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 498..526 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 527..529 FT /evidence="ECO:0007829|PDB:6RSU" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:4IWO" FT HELIX 535..539 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 544..546 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 548..571 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:6O8B" FT HELIX 577..603 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 605..647 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 648..651 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 680..714 FT /evidence="ECO:0007829|PDB:5EP6" FT STRAND 715..717 FT /evidence="ECO:0007829|PDB:5EP6" SQ SEQUENCE 729 AA; 83642 MW; B58E4FE1B502276D CRC64; MQSTSNHLWL LSDILGQGAT ANVFRGRHKK TGDLFAIKVF NNISFLRPVD VQMREFEVLK KLNHKNIVKL FAIEEETTTR HKVLIMEFCP CGSLYTVLEE PSNAYGLPES EFLIVLRDVV GGMNHLRENG IVHRDIKPGN IMRVIGEDGQ SVYKLTDFGA ARELEDDEQF VSLYGTEEYL HPDMYERAVL RKDHQKKYGA TVDLWSIGVT FYHAATGSLP FRPFEGPRRN KEVMYKIITG KPSGAISGVQ KAENGPIDWS GDMPVSCSLS RGLQVLLTPV LANILEADQE KCWGFDQFFA ETSDILHRMV IHVFSLQQMT AHKIYIHSYN TATIFHELVY KQTKIISSNQ ELIYEGRRLV LEPGRLAQHF PKTTEENPIF VVSREPLNTI GLIYEKISLP KVHPRYDLDG DASMAKAITG VVCYACRIAS TLLLYQELMR KGIRWLIELI KDDYNETVHK KTEVVITLDF CIRNIEKTVK VYEKLMKINL EAAELGEISD IHTKLLRLSS SQGTIETSLQ DIDSRLSPGG SLADAWAHQE GTHPKDRNVE KLQVLLNCMT EIYYQFKKDK AERRLAYNEE QIHKFDKQKL YYHATKAMTH FTDECVKKYE AFLNKSEEWI RKMLHLRKQL LSLTNQCFDI EEEVSKYQEY TNELQETLPQ KMFTASSGIK HTMTPIYPSS NTLVEMTLGM KKLKEEMEGV VKELAENNHI LERFGSLTMD GGLRNVDCL // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML //